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LAY SUMMARY 
 
The MHRA granted Bristol Laboratories Limited (licences) for the medicinal 
products Simvastatin 10mg, 20mg and 40mg Tablets (PL 17907/0125-7) on 
13
th September 2007. These are prescription-only medicines (POM) that reduce the 
amount of cholesterol and fatty substances called triglycerides in the blood. 
 
Simvastatin 10mg, 20mg and 40mg Tablets contain the active ingredient simvatstain, 
which belongs to a group of medicines known as “statins” or “HMG-CoA reductase 
inhibitors”. 
   
No new or unexpected safety concerns arose from these applications and it was 
therefore judged that the benefits of taking Simvastatin 10mg, 20mg and 40mg 
Tablets outweigh the risks, hence Marketing Authorisations have been granted. 
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INTRODUCTION 
 
Based on the review of the data on quality, safety and efficacy the UK granted 
marketing authorisations for the medicinal products Simvastatin 10mg, 20mg and 
40mg Tablets to Bristol Laboratories Limited (PL 17907/0125-7) on 
13
th September 2007. The products are prescription-only medicines. 
 
The applications were submitted as abridged applications according to Article 10.1 of 
Directive 2001/83/EC, as amended, claiming essential similarity to the original 
products Zocor 10mg, 20mg and 40mg Tablets (PL 00025/0241-3), which have been 
authorised to Merck, Sharp and Dohme in the UK since April 1989. 
 
The products contain the active ingredient simvastatin and are indicated for the 
treatment of hypercholesterolaemia and the reduction of cardiovascular mortality and 
morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes 
mellitus. 
 
Simvastatin is derived synthetically from a fermentation product of Aspergillus 
terreus. It is a lipid-lowering agent that reduces concentrations of total cholesterol, 
low-density lipoprotein, very low-density lipoprotein and plasma triglycerides, while 
elevating concentrations of high-density lipoprotein. It is an inactive lactone that, after 
oral ingestion, is hydrolysed to the corresponding β-hydroxyacid form. This is an 
inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an 
enzyme that catalyses the conversion of HMG-CoA to mevalonate – an early, rate-
limiting step in the biosynthesis of cholesterol. 
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PHARMACEUTICAL ASSESSMENT 
 
Active Substance 
INN:   Simvastatin 
 
Chemical Name:  (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-{2-
[(2R,4R)-tetra-hydro-4-hydroxy-6-oxo-2H-pyran-2-yl]-ethyl}-
1-naphthyl-2,2-dimethylbutyrate 
 
Molecular Formula:   C25H38O5
  
Chemical Structure: 
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Molecular Weight:   418.6 
 
Appearance:   White to off-white powder 
 
Properties:  Practically insoluble in water, freely soluble in ethanol, 
methanol and chloro-form; sparingly soluble in propylene 
glycol; very slightly soluble in hexane. 
 
Simvastatin is the subject of a European Pharmacopoeia monograph. 
 
Synthesis of the drug substance from the designated starting materials has been 
adequately described and appropriate in-process controls and intermediate 
specifications are applied. Satisfactory specification tests are in place for all starting 
materials and reagents and these are supported by relevant certificates of analysis. 
 
An appropriate specification is provided for the active substance simvastatin. 
Analytical methods are those of the European Pharmacopoeia, with addition tests for 
residual solvents that comply with the relevant ICH guidelines. 
 
Appropriate proof of structure has been supplied for the active pharmaceutical 
ingredient. 
 
All potential known impurities have been identified and characterised. 
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Batch analysis data are provided and comply with the proposed specification. 
 
Appropriate stability data have been generated showing the active substance to be a 
physically and chemically stable drug. The data support a retest period of 24 months 
with storage conditions “Store in original package” and “Keep drum tightly closed”. 
 
Other Ingredients 
Other ingredients consist of pharmaceutical excipients lactose anhydrous, cellulose 
microcrystalline, maize starch pregelatinised, butylhydroxyanisole E320, magnesium 
stearate, talc, hyprolose, hypromellose and titanium dioxide E171.  
 
All excipients have a respective European Pharmacopoeia monograph.  
 
Satisfactory certificates of analysis have been provided for all ingredients showing 
compliance with their respective monograph. 
 
Lactose anhydrous is the only ingredient that comes from an animal source. The 
lactose used to produce lactose monohydrate is sourced from healthy animals under 
the same conditions as milk for human consumption.  
 
Pharmaceutical development 
The objective of the pharmaceutical development programme was to produce products 
with 10mg, 20mg and 40mg simvastatin that are tolerable and can be considered as 
generic products to the originator products Zocor 10mg, 20mg and 40mg Tablets. 
 
The rationale for the type of pharmaceutical form developed and formulation variables 
evaluated during development have been stated and are satisfactory.   
 
The rationale and function of each excipient added is discussed.  Levels of each 
ingredient are typical for a product of this nature and have been optimised on the basis 
of results from development studies.  
 
Comparative in vitro dissolution profiles have been generated for the proposed and 
originator products with satisfactory results. Comparative impurity studies have also 
been undertaken. 
 
Manufacturing Process 
Satisfactory batch formulae have been provided for the manufacture of the product 
along with an appropriate account of the manufacturing process. The manufacturing 
process has been validated and has shown satisfactory results at pilot-scale. 
Additionally, a commitment has been provided that the first full-scale commercial 
production batches will be validated.  
 
Finished Product Specification 
The finished product specifications proposed for all strengths are acceptable. Test 
methods have been described and have been adequately validated, as appropriate. 
Batch data have been provided and comply with the release specification. Certificates 
of analysis have been provided for any working standards used. 
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Container-Closure System 
All strengths of tablet are packaged in either: 
1.   Polyethylene/polyvinylidene chloride/polyvinylchloride/aluminium blister strips 
in pack sizes of 14, 28, 30, 56, 60 and 100 tablets.  
2. Polyester/aluminium/polyethylene sachets in pack sizes of 14, 28, 30, 56, 60 and 
100 tablets. 
3.  High-density polyethylene containers with a child-resistant polypropylene closure 
and aluminium seal in pack sizes of 100 and 500 tablets. 
 
Satisfactory specifications and certificates of analysis have been provided for all 
packaging components. All primary packaging complies with the relevant regulations 
regarding materials for use in contact with food.  
 
The applicant has stated that not all packaging will be marketed in the UK and has 
provided assurances that they will submit mock-ups before launching any packaging 
types into the market. 
 
Stability of the product   
Stability studies were performed on pilot-scale batches of all strengths of finished 
product and all packaging types, in accordance with current guidelines. All results 
from stability studies on pilot batches were within specified limits. These data support 
a shelf-life of 3 years, with storage conditions ‘Do not store above 25°C’ and ‘Store in 
original packaging’.    
 
The applicant has committed to providing stability data for the first three 
production-scale batches of each strength of finished product. 
 
 
Bioequivalence/bioavailability 
Satisfactory Certificates of Analysis have been provided for the test and reference 
batches used in the bioequivalence study. 
 
SPC, PIL, Labels 
The SPC, PIL and Labels are pharmaceutically acceptable. 
 
CONCLUSION 
It is recommended that Marketing Authorisations are granted for these applications. 
 
The requirements for essential similarity of the proposed and reference products have been 
met with respect to qualitative and quantitative content of the active substance. In addition, 
similar dissolution profiles have been demonstrated for the proposed and reference 
products. 
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PRECLINICAL ASSESSMENT 
 
These applications for generic products claims essential similarity to Zocor 10mg, 
20mg and 40mg Tablets (Merck, Sharp and Dohme), which have been licensed within 
the EEA for over 10 years.  
 
No new preclinical data have been supplied with these applications and none are 
required for an application of this type. 
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CLINICAL ASSESSMENT 
 
1.   INTRODUCTION AND BACKGROUND 
These are standard abridged national applications for Simvastatin 10mg, 20mg and 
40mg Tablets submitted under Article 10.1 of Directive 2001/83/EC, as amended. The 
applications cross-refer to Zocor 10mg, 20mg and 40mg Tablets (Merck, Sharp and 
Dohme), which have been authorised in the EU for more than 10 years.  
 
2.   INDICATIONS  
Hypercholesterolaemia 
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, 
when response to diet and other non-pharmacological treatments (e.g. exercise, weight 
reduction) is inadequate. 
 
Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-
lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. 
 
Cardiovascular prevention 
Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic 
cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, 
as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 
5.1). 
 
The indications proposed are consistent with those for the originator products and are, 
therefore, satisfactory. 
 
3.   DOSE & DOSE SCHEDULE  
The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of 
dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 
80mg/day given as a single dose in the evening. The 80-mg dose is only recommended in 
patients with severe hypercholesterolaemia and high risk for cardiovascular complications. 
 
Hypercholestrolaemia 
The patient should be placed on a standard cholesterol-lowering diet, and should continue on 
this diet during treatment with Simvastatin tablets. The usual starting dose is 10-20mg/day 
given as a single dose in the evening. Patients who require a large reduction in LDL-C (more 
than 45%) may be started at 20-40 mg/day given as a single dose in the evening. Adjustments 
of dosage, if required, should be made as specified above. 
 
Homozygous familial hypercholesterolaemia 
Based on the results of a controlled clinical study, the recommended dosage is Simvastatin 
tablets 40mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an 
evening dose of 40 mg. Simvastatin tablets should be used as an adjunct to other lipid-
lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are 
unavailable.  
 
Cardiovascular prevention 
The usual dose of Simvastatin tablets is 20 to 40 mg/day given as a single dose in the evening 
in patients at high risk of coronary heart disease (CHD, with or without hyperlipidaemia). 
Drug therapy can be initiated simultaneously with diet and exercise. Adjustments of dosage, if 
required, should be made as specified above.  
 
Concomitant therapy 
Simvastatin is effective alone or in combination with bile acid sequestrants. Dosing should 
occur either > 2 hours before or > 4 hours after administration of a bile acid sequestrant.  
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In patients taking cyclosporine, danazol, gemfibrozil, other fibrates (except fenofibrate) or 
lipid-lowering doses (≥ 1g/day) of niacin concomitantly with ‘Simvastatin tablets’, the dose of 
‘Simvastatin tablets’ should not exceed 10 mg/day. In patients taking amiodarone or 
verapamil concomitantly with Simvastatin tablets, the dose of Simvastatin tablets should not 
exceed 20mg/day. (See sections 4.4 and 4.5)  
 
Dosage in renal insufficiency 
No modification of dosage should be necessary in patients with moderate renal insufficiency. 
In patients with severe renal insufficiency (creatinine clearance <30ml/min), dosages above 10 
mg/day should be carefully considered and, if deemed necessary, implemented cautiously.  
 
Use in the elderly 
No dosage adjustment is necessary 
 
Use in children and adolescents 
Efficacy and safety of use in children have not been established. Therefore Simvastatin  is not 
recommended for paediatric use. 
 
The dose and dose schedule proposed are consistent with those for the originator 
products and are, therefore, satisfactory. 
 
4.   CLINICAL PHARMACOLOGY  
With the exception of the bioequivalence study comparing the proposed product to Zocor 
40mg Tablets, no formal data are provided and none are required for these applications.  
 
4.1 Bioequivalence   
The bioavailability of the proposed simvastatin 40mg tablet (Test) was compared to the 
reference product Zocor 40mg tablet (Reference) from the German market by comparing 
the rate and extent of absorption of simvastatin hydroxy acid, the active metabolite 
formed in the body by conversion from the inactive lactone simvastatin after 
administration. 
 
The study was a randomised, two-way, single-dose crossover design using healthy 
volunteers. The products were administered after a 10-hour supervised fast. Blood 
samples were collected over a 24-hour period.   
 
The essential pharmacokinetic parameters of simvastatin hydroxy acid for the two 
preparations are summarised below (Table I: log-normal distribution; Table II: normal 
distribution), while in the following figure, the mean simvastatin hydroxy acid plasma 
levels are shown for both products over the 24-hour period. 
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Table 1:   Results of Simvastatin hydroxy acid (log-normal distribution) 
                 Parameter      Reference 
         (R) 
      Test 
        (T) 
     90% Confidence 
         Interval (%) 
 Mean Ratio 
       (%)* 
   GMEAN       14.075       14.530 
      GSD       0.4768       0.5156 
AUC(0-t)
(ng*h*mL
-1) 
   %CVres                       22.37 
    95.48 – 111.62** 
    95.55 – 111.54*** 
     
    103.23 
   GMEAN       16.590       17.774 
      GSD       0.4455        0.4671 
AUC(0-inf)
(ng*h*mL
-1) 
   %CVres                       21.49 
    99.35 – 115.53** 
    99.45 – 115.42*** 
 
    107.14 
   GMEAN         1.403        1.398 
      GSD        0.5710       0.6153 
Cmax
(ng*mL
-1) 
   %CVres         33.02   
     89.11 – 111.36** 
     89.00 – 111.50*** 
 
     99.62 
   GMEAN        0.0846       0.0787 
      GSD        0.3059       0.3318 
Cmax/AUC(0-inf)
(h
-1) 
   %CVres                       24.41 
     85.47 – 101.15** 
     85.46 – 101.16*** 
 
     92.98 
Notes: 
GMEAN = exp (mean of In transformed values) 
LSM values are the same as means because the study is balanced and there were no missing 
pharmacokinetic parameters values. 
GSD = standard deviation of In transformed values 
%Cvres -= 100 √exp (σ2)-1 
σ = root MSE obtained in ANOVA calculation of In transformed values (cf. Appendix III) (In denotes 
loge     logarithms) 
*:        geometric mean of individual “test/reference” pair ratios 
**:    exp (Conventional confidence interval for the mean of individual “test/reference” pair rations 
after logarithmic transformation of the data) expressed in % of the reference mean 
***:   confidence intervals calculated on the bases of reference and test means of In transformed data 
and root MSE 
 
Table 2:   Results of Simvastatin hydroxy acid (normal distribution) 
                  Parameter      Reference 
         (R) 
      Test 
        (T) 
    90% Confidence 
        Interval (%) 
 Mean Ratio 
       (%)* 
   MEAN       15.792      16.534 
      SD         8.522        8.576 
AUC(0-t)
(ng*h*mL
-1) 
   %CV        53.96       51.87 
     
    95.13 – 114.27 
     
    104.70 
   MEAN       18.330      19.724 
      SD         8.991        9.022 
AUC(0-inf)
(ng*h*mL
-1) 
   %CV        49.05       45.74 
     
    99.07 – 116.14 
 
    107.60 
   MEAN         1.677       1.694 
      SD        1.325       1.153 
Cmax
(ng*mL
-1) 
   %CV        78.99       68.05  
      
     81.84 – 120.25 
 
     101.04 
    MAX        12.00       10.00 
     MIN         1.50         2.00 
tmax
(h) 
 MEDIAN         4.00         4.00 
  
   MEAN        7.724        9.169 
      SD        4.110        4.886 
t1/2e
(h) 
    %CV        53.21       53.29 
 
     012.80 – 134.62 
    
     118.71 
   MEAN     0.11702     0.10254 
      SD     0.06026     0.06224 
Kel
(h
-1) 
    %CV        51.50        60.70 
 
     74.47 – 100.78 
 
     87.63 
Notes: 
MEAN – arithmetic mean 
LSM values are the same as means because the study is balanced and there were no missing 
pharmacokinetic parameters values. 
SD = standard deviation 
%CV – SD/MEAN * 100 
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Figure:  Mean Simvastatin hydroxy acid plasma levels 
 
 
 
Based on these results, it can be accepted that the Test and Reference products are 
bioequivalent with respect to rate and extent of absorption. Although the German version 
of the originator product (Zocor 40mg Tablets) was used in these bioequivalence studies, 
it has been shown that this can be considered as identical qualitatively and quantitatively 
to the UK originator product. 
 
Assessor's Comment 
Bioequivalence has been satisfactorily demonstrated for the 40mg product, in 
accordance with CPMP criteria. These products meet all the criteria as specified in the 
Note for Guidance on the investigation of bioavailability and bioequivalence 
(CPMP/EWP/QWP/1401/98). Hence, the results and conclusions of the 
bioequivalence study on the 40mg strength can be extrapolated to the other strength 
tablets. 
 
5.   EFFICACY  
No new data on the efficacy of simvastatin are submitted and none are required for 
this type of application.  
 
6.   SAFETY 
No new data on the safety of simvastatin are submitted and none are required for this 
type of application.  
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7.   EXPERT REPORTS  
A clinical expert report is provided, written by an appropriately qualified Doctor. It 
includes a suitable review of the bioequivalence study. 
 
8.   SUMMARY OF PRODUCT CHARACTERISTICS (SPC)  
The SPCs are consistent with the approved SPCs for the originator products Zocor 
10mg, 20mg and 40mg Tablets and are satisfactory. 
 
9.   PATIENT INFORMATION LEAFLET (PIL)  
The PIL has been provided and is consistent the SPC. 
 
10. LABELLING 
Labelling text for all strengths are satisfactory. Mock-ups of labelling intended for 
marketing are satisfactory and comply with current regulations. 
 
The applicant has stated that not all proposed pack sizes will be marketed initially, but 
has provided assurances that mock-ups will be submitted for assessment before any 
further pack sizes are marketed. 
 
11.   APPLICATION FORM (MAA)  
The MAA form is satisfactory.  
 
12.   DISCUSSION 
Bioequivalence has been satisfactorily demonstrated for the 40mg product in 
accordance with CPMP criteria. As these products meet all the criteria as specified in 
the Note for Guidance on the investigation of bioavailability and bioequivalence 
(CPMP/EWP/QWP/1401/98), the results and conclusions of the bioequivalence study 
on the 40mg strength can be extrapolated to the other strength tablets. 
 
The SPC and PIL are consistent with those approved in the UK for the originator 
product Zocor 10mg, 20mg and 40mg Tablets and are satisfactory.  
  
13.   MEDICAL CONCLUSION 
Marketing authorisations may be granted for these products. 
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OVERALL CONCLUSION AND RISK BENEFIT ASSESSMENT 
 
QUALITY 
The important quality characteristics of Simvastatin 10mg, 20mg and 40mg Tablets 
are well-defined and controlled. The specifications and batch analytical results 
indicate consistency from batch to batch. There are no outstanding quality issues that 
would have a negative impact on the benefit/risk balance.  
 
PRECLINICAL  
No new preclinical data were submitted and none are required for applications of this 
type. 
 
EFFICACY 
Bioequivalence has been demonstrated between the applicant’s Simvastatin 40mg 
Tablets and Zocor 40mg Tablets (Merck, Sharp and Dohme). As these products meet 
all the criteria as specified in the Note for Guidance on the investigation of 
bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98), the results and 
conclusions of the bioequivalence study on the 40mg strength can be extrapolated to 
the other strength tablets. 
 
No new or unexpected safety concerns arise from these applications. 
 
The SPC, PIL and labelling are satisfactory and consistent with that for Zocor Tablets.  
 
RISK BENEFIT ASSESSMENT 
The quality of the product is acceptable and no new preclinical or clinical safety 
concerns have been identified. The bioequivalence study supports the claim that the 
applicant’s products and the innovator products are interchangeable. Extensive 
clinical experience with simvastatin is considered to have demonstrated the 
therapeutic value of the compound. The risk benefit is, therefore, considered to be 
positive. 
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SIMVASTATIN 10MG TABLETS (PL 17907/0125) 
SIMVASTATIN 20MG TABLETS (PL 17907/0126) 
SIMVASTATIN 40MG TABLETS (PL 17907/0127) 
 
 
STEPS TAKEN FOR ASSESMENT 
  
1  The MHRA received the marketing authorisation applications on 2
nd July 2004 
 
2  Following standard checks and communication with the applicant the MHRA 
considered the applications valid on 4
th August 2004 
 
3  Following assessment of the applications the MHRA requested further 
information relating to the clinical dossiers on 19
th May 2005, and further 
information relating to the quality dossiers on 6
th April 2005, 5
th October 2005, 
17
th July 2006 and 9
th February 2007. 
 
4  The applicant responded to the MHRA’s requests, providing further information 
on 9
th June 2005 for the clinical dossiers, and again on 19
th August 2005, 31
st 
October 2005, 21
st October 2006 and 23
rd March 2007 for the quality dossiers. 
 
5  The applications were determined on 13
th September 2007 
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STEPS TAKEN AFTER AUTHORISATION - SUMMARY 
  
Date 
submitted 
Application 
type 
Scope Outcome 
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SUMMARY OF PRODUCT CHARACTERISTICS 
 
1  NAME OF THE MEDICINAL PRODUCT 
Simvastatin 10 mg Tablets 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each tablet contains 10mg of simvastatin 
For excipients, see 6.1 
 
3 PHARMACEUTICAL  FORM 
Film-coated tablets 
 
White, oblong, biconvex tablets, scored on one side, embossed with “10” on the scored side 
and with “SVT” on the opposite side. 
OR 
White oblong, biconvex tablets, scored on both sides, embossed with “SVT” and  “10” on one 
side. 
 
4 CLINICAL  PARTICULARS 
4.1 Therapeutic  indications 
Hypercholesterolaemia 
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, 
when response to diet and other non-pharmacological treatments (e.g. exercise, weight 
reduction) is inadequate. 
 
Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-
lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. 
 
Cardiovascular prevention 
Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic 
cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, 
as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 
5.1). 
 
4.2  Posology and method of administration 
The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of 
dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 
80mg/day given as a single dose in the evening. The 80-mg dose is only recommended in 
patients with severe hypercholesterolaemia and high risk for cardiovascular complications. 
 
Hypercholestrolaemia 
The patient should be placed on a standard cholesterol-lowering diet, and should continue on 
this diet during treatment with Simvastatin tablets. The usual starting dose is 10-20mg/day 
given as a single dose in the evening. Patients who require a large reduction in LDL-C (more 
than 45%) may be started at 20-40 mg/day given as a single dose in the evening. Adjustments 
of dosage, if required, should be made as specified above. 
 
Homozygous familial hypercholesterolaemia 
Based on the results of a controlled clinical study, the recommended dosage is Simvastatin 
tablets 40mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an 
evening dose of 40 mg. Simvastatin tablets should be used as an adjunct to other lipid-
lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are 
unavailable.  
 
Cardiovascular prevention 
The usual dose of Simvastatin tablets is 20 to 40 mg/day given as a single dose in the evening 
in patients at high risk of coronary heart disease (CHD, with or without hyperlipidaemia). 
Drug therapy can be initiated simultaneously with diet and exercise. Adjustments of dosage, if 
required, should be made as specified above.  
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Concomitant therapy 
Simvastatin is effective alone or in combination with bile acid sequestrants. Dosing should 
occur either > 2 hours before or > 4 hours after administration of a bile acid sequestrant.  
 
In patients taking cyclosporine, danazol, gemfibrozil, other fibrates (except fenofibrate) or 
lipid-lowering doses (≥ 1g/day) of niacin concomitantly with ‘Simvastatin tablets’, the dose of 
‘Simvastatin tablets’ should not exceed 10 mg/day. In patients taking amiodarone or 
verapamil concomitantly with Simvastatin tablets, the dose of Simvastatin tablets should not 
exceed 20mg/day. (See sections 4.4 and 4.5)  
 
Dosage in renal insufficiency 
No modification of dosage should be necessary in patients with moderate renal insufficiency. 
In patients with severe renal insufficiency (creatinine clearance <30ml/min), dosages above 10 
mg/day should be carefully considered and, if deemed necessary, implemented cautiously.  
 
Use in the elderly 
No dosage adjustment is necessary 
 
Use in children and adolescents 
Efficacy and safety of use in children have not been established. Therefore Simvastatin  is not 
recommended for paediatric use. 
 
4.3 Contraindications 
•  Hypersensitivity to simvastatin or to any of the excipients 
•  Active liver disease or unexplained persistent elevations of serum transaminases 
•  Pregnancy and lactation (see section 4.6) 
•  Concomitant administration of potent CYP3A4 inhibitors (e.g itraconazole, ketoconazole, 
HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone) (see 
section 4.5). 
 
4.4  Special warnings and precautions for use 
Myopathy/Rhabdomyolysis 
Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes  myopathy 
manifested  as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times 
the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with 
or without acute renal failure secondary to myoglobinuria, and very rare fatalities have 
occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory 
activity in plasma. 
 
As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is dose 
related. In a clinical trial database in which 41,050 patients were treated with Simvastatin with 
24,747 (approximately 60 %) treated for at least 4 years, the incidence of myopathy was 
approximately 0.02 %, 0.08 % and 0.53 % at 20, 40 and 80 mg/day, respectively. In these 
trials, patients were carefully monitored and some interacting medicinal products were 
excluded.  
 
Creatine Kinase measurement  
Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence 
of any plausible alternative cause of CK increase as this makes value interpretation difficult. If 
CK levels are significantly elevated at baseline (>5 x ULN), levels should be re-measured 
within 5 to 7 days later to confirm the results. 
 
Before the treatment 
All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, 
should be advised of the risk of myopathy and told to report promptly any unexplained muscle 
pain, tenderness or weakness. 
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Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis. In 
order to establish a reference baseline value, a CK level should be measured before starting a 
treatment in the following situations:    
•  Elderly (age > 70 years) 
•  Renal impairment 
•  Uncontrolled hypothyroidism 
•  Personal or familial history of hereditary muscular disorders 
•  Previous history of muscular toxicity with a statin or fibrate 
•  Alcohol abuse 
 
In such situations, the risk of treatment should be considered in relation to possible benefit, 
and clinical monitoring is recommended. If a patient has previously experienced a muscle 
disorder on a fibrate or a statin, treatment with a different member of the class should only be 
initiated with caution. If CK levels are significantly elevated at baseline (>5 x ULN), 
treatment should not be started.  
 
Whilst on treatment  
If muscle pain, weakness or cramps occur whilst a patient is receiving treatment with a statin, 
their CK levels should be measured. If these levels are found, in the absence of strenuous 
exercise, to be significantly elevated (>5 x ULN), treatment should be stopped. If muscular 
symptoms are severe and cause daily discomfort, even if CK levels are <5 x ULN, treatment 
discontinuation may be considered. If myopathy is suspected for any other reason, treatment 
should be discontinued.  
 
If symptoms resolve and CK levels return to normal, then re-introduction of the statin or 
introduction of an alternative statin may be considered at the lowest dose and with close 
monitoring.  
 
Therapy with simvastatin should be temporarily stopped a few days prior to elective major 
surgery and when any major medical or surgical condition supervenes.  
 
Measures to reduce the risk of myopathy caused by medicinal product interactions (see also 
section 4.5)  
The risk of myopathy and rhabdomyolysis is significantly increased by concomitant use of 
simvastatin with potent inhibitors of CYP3A4 (such as itraconazole, ketoconazole, 
erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone), as well as 
gemfibrozil, ciclosporine and danazol (see section 4.2)  
 
The risk of myopathy and rhabdomyolysis is also increased by concomitant use of other 
fibrates, lipid-lowering doses (≥ 1 g/day) of niacin or by concomitant use of amiodarone or 
verapamil with higher doses of simvastatin (see sections 4.2 and 4.5). There is also a slight 
increase in risk when dilitiazem is used with simvastatin 80 mg.  
 
Consequently, regarding CYP3A4 inhibitors, the use of simvastatin concomitantly with 
itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin, 
telithromycin and nefazodone is contraindicated (see sections 4.3 and 4.5). If treatment with 
itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, 
therapy with simvastatin must be suspended during the course of treatment. Moreover, caution 
should be exercised when combining simvastatin with certain other less potent CYP3A4 
inhibitors: cyclosporine, verapamil, diltiazem (see sections 4.2 and 4.5). Concomitant intake 
of grapefruit juice and simvastatin should be avoided.  
 
The dose of simvastatin should not exceed 10mg daily in patients receiving concomitant 
medication with ciclosporine, danazol, gemfibrozil, or lipid-lowering doses (≥ 1 g/day) of 
niacin. The combined use of simvastatin with gemfibrozil should be avoided, unless the 
benefits are likely to outweigh the increased risks of this drug combination. The benefits of 
the combined use of simvastatin 10 mg daily with other fibrates (except fenofibrate), niacin or 
cyclosporine should be carefully weighed against the potential risks of these combinations. 
(See sections 4.2 and 4.5). 
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Caution should be used when prescribing fenofibrate with simvastatin, as either agent can 
cause myopathy when given alone.  
 
The combined use of simvastatin at doses higher than 20mg daily with amiodarone or 
verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk 
of myopathy (see sections 4.2 and 4.5). 
 
Hepatic effects 
In clinical studies, persistent increases (to > 3 x ULN) in serum transaminases have occurred 
in a few adult patients who received simvastatin. When simvastatin was interrupted or 
discontinued in these patients, the transaminase levels usually fell slowly to pre-treatment 
levels.  
 
It is recommended that liver function tests be performed before treatment begins and 
thereafter when clinically indicated. Patients titrated to the 80-mg dose should receive an 
additional test prior to titration, 3 months after titration to the 80-mg dose, and periodically 
thereafter (e.g. semi-annually) for the first year of treatment. Special attention should be paid 
to patients who develop elevated serum transaminase levels, and in these patients, 
measurements should be repeated promptly and then performed more frequently. If the 
transaminase levels show evidence of progression, particularly if they rise to 3 x ULN and are 
persistent, simvastatin should be discontinued.  
 
The product should be used with caution in patients who consume substantial quantities of 
alcohol.  
 
As with other lipid-lowering agents, moderate (<3 x ULN) elevations of serum transaminases 
have been reported following therapy with simvastatin. These changes appeared soon after 
initiation of therapy with simvastatin, were often transient, were not accompanied by any 
symptoms and interruption of treatment was not required. 
 
Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase 
deficiency or glucose-galactose malabsorption should not take this medicine. 
 
4.5  Interaction with other medicinal products and other forms of interaction 
Pharmacodynamic interactions 
Interactions with lipid-lowering medicinal products that can cause myopathy when given 
alone 
The risk of myopathy, including rhabdomyolysis, is increased during concomitant 
administration with fibrates and niacin (nicotinic acid) (≥ 1 g/day). Additionally, there is a 
pharmacokinetic interaction with gemfibrozil resulting in increased simvastatin plasma levels 
(see Pharmacokinetic interactions and sections 4.2 and 4.4). When simvastatin and fenofibrate 
are given concomitantly, there is no evidence that the risk of myopathy exceeds the sum of the 
individual risks of each agent. Adequate pharmacovigilance and pharmacokinetic data are not 
available for other fibrates.  
 
Pharmacokinetic interactions 
Prescribing recommendations for interacting agents are summarized in the table below 
(further details are provided in the text; see also sections 4.2, 4.3, and 4.4). 
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Drug Interactions Associated with Increased  
Risk of Myopathy/Rhabdomyolysis 
Interacting agents  Prescribing recommendations 
Potent CYP3A4 inhibitors: 
Itraconazole 
Ketoconazole 
Erythromycin 
Clarithromycin 
Telithromycin 
HIV protease inhibitors 
Nefazodone 
 
Contraindicated with simvastatin 
Gemfibrozil  Avoid but if necessary, do not exceed 10 mg simvastatin 
daily 
Ciclosporin 
Danazol 
Other fibrates (except 
fenofibrate) 
Niacin (≥1 g/day) 
Do not exceed 10 mg simvastatin daily 
Amiodarone 
Verapamil 
Do not exceed 20 mg simvastatin daily 
Diltiazem  Do not exceed 40 mg simvastatin daily 
Grapefruit juice  Avoid grapefruit juice when taking simvastatin 
 
Effects of other medicinal products on simvastatin  
Interactions involving CYP3A4 
Simvastatin is a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome P450 
3A4 increase the risk of myopathy and rhabdomyolysis by increasing the concentration of 
HMG-CoA reductase inhibitory activity in plasma during simvastatin therapy. Such inhibitors 
include itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease 
inhibitors, and nefazodone. Concomitant administration of itraconazole resulted in a more 
than 10-fold increase in exposure to simvastatin acid (the active beta-hydroxyacid metabolite). 
Telithromycin caused an 11-fold increase in exposure to simvastatin acid.  
 
Therefore, combination with itraconazole, ketoconazole, HIV protease inhibitors, 
erythromycin, clarithromycin, telithromycin and nefazodone is contraindicated. If treatment 
with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is 
unavoidable, therapy with simvastatin must be suspended during the course of treatment. 
Caution should be exercised when combining simvastatin with certain other less potent 
CYP3A4 inhibitors: ciclosporine, verapamil, dilitiazem (see sections 4.2 and 4.4). 
 
Ciclosporine 
The risk of myopathy/rhabdomyolysis is increased by concomitant administration of 
ciclosporine particularly with higher doses of simvastatin (see sections 4.2 and 4.4). 
Therefore, the dose of simvastatin should not exceed 10 mg daily in patients receiving 
concomitant medication with cyclosporine. Although the mechanism is not fully understood, 
ciclosporine has been shown to increase the AUC HMG-CoA reductase inhibitors. The 
increase in AUC of simvastatin acid presumably due, in part, to inhibition of CYP3A4.    
 
Danazol 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
danazol with higher doses of simvastatin (see sections 4.2 and 4.4). 
 
Gemfibrozil 
Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of 
the glucuronidation pathway (see sections 4.2 and 4.4). 
 
Amiodarone and verapamil 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
amiodarone or verapamil with higher doses of simvastatin (see section 4.4). In an ongoing 
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clinical trial, myopathy has been reported in 6% of patients receiving simvastatin 80 mg and 
amiodarone. 
 
An analysis of the available clinical trials showed an approximately 1 % incidence of 
myopathy in patients receiving simvastatin 40mg or 80 mg and verapamil. In a 
pharmacokinetic study, concomitant administration with verapamil resulted in a 2.3-fold 
increase in exposure of simvastatin acid, presumably due, in part, to inhibition of CYP3A4. 
Therefore, the dose of simvastatin should not exceed 20mg daily in patients receiving 
concomitant medication with amiodarone or verapamil, unless the clinical benefit is likely to 
outweigh the increased risk of myopathy and rhabdomyolysis. 
 
Diltiazem 
An analysis of the available clinical trials showed a 1 % incidence of myopathy in patients 
receiving simvastatin 80mg and diltiazem. The risk of myopathy in patients taking simvastatin 
40 mg was not increased by concomitant diltiazem (see section 4.4). In a pharmacokinetic 
study, concomitant administration of diltiazem caused a 2.7-fold increase in exposure of 
simvastatin acid, presumably due to inhibition of CYP3A4. Therefore, the dose of simvastatin 
should not exceed 40 mg daily in patients receiving concomitant medication with diltiazem, 
unless the clinical benefit is likely to outweigh the increased risk of myopathy and 
rhabdomyolysis.  
 
Grapefruit juice 
Grapefruit juice inhibits cytochrome P450 3A4. Concomitant intake of large quantities (over 1 
litre daily) of grapefruit juice and simvastatin resulted in a 7-fold increase in exposure to 
simvastatin acid. Intake of 240 ml of grapefruit juice in the morning and simvastatin in the 
evening also resulted in a 1.9-fold increase. Intake of grapefruit juice during treatment with 
simvastatin should therefore be avoided.  
 
Effects of simvastatin on the pharmacokinetics of other medicinal products 
Simvastatin does not have an inhibitory effect on cytochrome P450 3A4. Therefore, 
simvastatin is not expected to affect plasma concentrations of substances metabolised via 
cytochrome P450 3A4. 
 
Oral anticoagulants 
In two clinical studies, one in normal volunteers and the other in hypercholesterolaemic 
patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin 
anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), 
increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, 
respectively. Very rare cases of elevated INR have been reported. In patients taking coumarin 
anticoagulants, prothrombin time should be determined before starting simvastatin and 
frequently enough during early therapy to ensure that no significant alteration of prothrombin 
time occurs. Once a stable prothrombin time has been documented, prothrombin times can be 
monitored at the intervals usually recommended for patients on coumarin anticoagulants. If 
the dose of simvastatin is changed or discontinued, the same procedure should be repeated. 
Simvastatin therapy has not been associated with bleeding or with changes in prothrombin 
time in patients not taking anticoagulants.  
 
4.6 Pregnancy  and  lactation 
Pregnancy 
Simvastatin is contraindicated during pregnancy (see section 4.3). 
 
Safety in pregnant women has not been established. No controlled clinical trials with 
simvastatin have been conducted in pregnant women. Rare reports of congenital anomalies 
following intrauterine exposure to HMG-CoA reductase inhibitors have been received. 
However, in an analysis of approximately 200 prospectively followed pregnancies exposed 
during the first trimester to simvastatin or another closely related HMG-CoA reductase 
inhibitor, the incidence of congenital anomalies was comparable to that seen in the general 
population. This number of pregnancies was statistically sufficient to exclude a 2.5-fold or 
greater increase in congenital anomalies over the background incidence.  
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Although there is no evidence that the incidence of congenital anomalies in offspring of 
patients taking simvastatin or another closely related HMG-CoA reductase inhibitor differs 
from that observed in the general population, maternal treatment with simvastatin  may reduce 
the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis. 
Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering 
medicinal products during pregnancy should have little impact on the long-term risk 
associated with primary hypercholesterolaemia. For these reasons, simvastatin should not be 
used in women who are pregnant, trying to become pregnant or suspect they are pregnant. 
Treatment with simvastatin should be suspended for the duration of pregnancy or until it has 
been determined that the woman is not pregnant. (See section 4.3). 
 
Lactation 
It is not known whether simvastatin or its metabolites are excreted in human milk. Because 
many medicinal products are excreted in human milk and because of the potential for serious 
adverse reactions, women taking simvastatin should not breast-feed their infants (see section 
4.3). 
 
4.7  Effects on ability to drive and use machines 
Simvastatin has no or negligible influence on the ability to drive and use machines.  
 
However, when driving vehicles or operating machines, it should be taken into account that 
dizziness has been reported rarely in post-marketing experiences. 
 
4.8 Undesirable  effects 
 The frequencies of the following adverse events, which have been reported during clinical 
studies and/or post-marketing use, are categorized based on an assessment of their incidence 
rates in large, long-term, placebo-controlled, clinical trials including HPS and 4S with 20,536 
and 4,444 patients, respectively (see section 5.1). For HPS, only serious adverse events were 
recorded as well as myalgia, increases in serum transaminases and CK. For 4S, all the adverse 
events listed below were recorded. If the incidence rates on simvastatin were less than or 
similar to that of placebo in these trials, and there were similar reasonably causally related 
spontaneous report events, these adverse events are categorized as ‘rare’.  
 
In HPS (see section 5.1) involving 20,536 patients treated with 40mg/day of simvastatin 
(n=10,269) or placebo (n=10,267), the safety profiles were comparable between patients 
treated with simvastatin  40 mg and patients treated with placebo over the mean 5 years of the 
study. Discontinuation rates due to side effects were comparable (4.8 % in patients treated 
with simvastatin 40mg compared with 5.1% in patients treated with placebo). The incidence 
of myopathy was <0.1% in patients treated with simvastatin  40 mg. Elevated transaminases 
(>3 x ULN confirmed by repeat test) occurred in 0.21 % (n=21) of patients treated with 
simvastatin 40mg compared with 0.09% (n = 9) of patients treated with placebo.  
 
The frequencies of adverse events are ranked according to the following: Very common (> 
1/10), Common (≥ 1/100, <1/10), Uncommon (≥ 1/1000, <1/100), Rare (≥ 1/10,000, 
<1/1000), Very Rare (<1/10,000) including isolated reports.  
 
Blood and lymphatic system disorders:  
Rare: anaemia 
 
Nervous system disorders:  
Rare: headache, paresthesia, dizziness, peripheral neuropathy 
 
Gastrointestinal disorders: 
Rare: constipation, abdominal pain, flatulence, dyspepsia, diarrhoea, nausea, vomiting, 
pancreatitis 
 
Hepato-biliary disorders: 
Rare: hepatitis/jaundice 
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Skin and subcutaneous tissue disorders: 
Rare: rash, pruritus, alopecia 
 
Musculoskeletal, connective tissue and bone disorders: 
Rare: myopathy, rhabdomyolysis (see section 4.4), myalgia, muscle cramps 
General disorders and administration site conditions:  
Rare: asthenia  
 
An apparent hypersensitivity syndrome has been reported rarely which has included some of 
the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, 
dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis and 
arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise. 
 
Investigations: 
Rare: increases in serum transaminases (alanine aminotransferase, aspartate aminotransferase, 
γ-glutamyl transpeptidase) (see section 4.4 Hepatic effects), elevated alkaline phosphatase; 
increase in serum CK levels (see section 4.4). 
 
4.9 Overdose 
To date, a few cases of overdosage have been reported; the maximum dose was 3.6 g. All 
patients recovered without sequelae. There is no specific treatment in the event of overdose. In 
this case, symptomatic and supportive measures should be adopted. 
 
5 PHARMACOLOGICAL  PROPERTIES 
5.1 Pharmacodynamic  properties 
Pharmacotherapeutic group: HMG-CoA reductase inhibitor 
ATC-Code: C10A A01 
 
After oral ingestion, simvastatin, which is an active lactone, is hydrolyzed in the liver to the 
corresponding active beta-hydroxyacid form which has a potent activity in inhibiting HMG-
CoA reductase (3 hydroxy – 3 methylglutaryly CoA reductase). This enzyme catalyses the 
conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthesis of 
cholesterol.  
 
Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations. LDL 
is formed from very-low-density protein (VLDL) and is catabolised predominantly by the 
high affinity LDL receptor. The mechanism of the LDL-lowering effect of ‘Simvastatin 
tablets’ may involve both reduction of VLDL-chlolestrol (VLDL-C) concentration and 
induction of the LDL receptor, leading to reduced production and increased catabolism of 
LDL-C. Apolipoprotein B also falls substantially during treatment with ‘Simvastatin tablets’. 
In addition, ‘Simvastatin tablets’ moderately increases HDL-C and reduces plasma TG. As a 
result of these changes the ratios of total to HDL-C and LDL-to HDL-C are reduced. 
 
High Risk of Coronary Heart Disease (CHD) or Existing Coronary Heart Disease 
In the Heart Protection Study (HPS), the effects of therapy with Simvastatin tablets were 
assessed in 20,536 patients (age 40-48 years), with or without hyperlipidaemia, and with 
coronary heart disease, other occlusive arterial disease or diabetes mellitus. In this study, 
10,269 patients were treated with simvastatin tablets 40mg/day and 10,267 patients were 
treated with placebo for a mean duration of 5 years. At baseline, 6,793 patients (33 %) had 
LDL-C levels below 116 mg/dL; 5,063 patients (25 %) had levels between 116 mg/dL and 
135mg/dL; and 8,680 patients (42 %) had levels greater than 135 mg/dL. 
 
Treatment with Simvastatin tablets 40 mg/day compared with placebo significantly reduced 
the risk of all cause mortality (1328 [12.9%] for simvastatin-treated patients versus 1507 [14.7 
%] for patients given placebo; p=0.0003), due to an 18% reduction in coronary death rate (587 
[5.7 %] versus 707 [6.9 %]; p=0.0005; absolute risk reduction of 1.2 %). The reduction in 
non-vascular deaths did not reach statistical significance. ‘Simvastatin tablets’ also decreased 
the risk of major coronary events (a composite endpoint comprised of non-fatal MI or CHD 
death) by 27 % (p<0.0001). Simvastatin tablets reduced the need for undergoing coronary 
revascularization procedures (including coronary artery bypass grafting or percutaneous 
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transluminal coronary angioplasty) and peripheral and other non-coronary revascularization 
procedures by 30 % (p<0.0001) and 16 % (p = 0.006), respectively. Simvastatin tablets 
reduced the risk of stroke by 25 % (p<0.0001), attributable to a 30 % reduction in ischemic 
stroke (p<0.0001). In addition, within the subgroup of patients with diabetes, simvastatin 
tablets reduced the risk of developing macrovascular complications, including peripheral 
revascularization procedures (surgery or angioplasty), lower limb amputations, or leg ulcers 
by 21 % (p = 0.0293). The proportional reduction in event rate was similar in each subgroup 
of patients studied, including those without coronary disease but who had cerebrovascular or 
peripheral artery disease, men and women, those aged either under or over 70 years at entry 
into study, presence or absence of hypertension, and notably those with LDL cholesterol 
below 3.0 mmol/l at inclusion.  
 
In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with simvastatin on 
total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 
mg/dL (5.5-8.0 mmol/L). In this multicenter, randomised, double-blind, placebo controlled 
study, patients with angina or a previous myocardial infarction (MI) were treated with diet, 
standard care, and either simvastatin  20-40 mg/day (n = 2,221) or placebo (n=2,223) for a 
median duration of 5.4 years. Simvastatin tablets reduced the risk of death by 30 % (absolute 
risk reduction of 3.3 %). The risk of CHD death was reduced by 42 % (absolute risk reduction 
of 3.5 %). Simvastatin also decreased the risk of having major coronary events (CHD death 
plus hospital-verified and silent nonfatal MI) by 34 %. Furthermore, simvastatin significantly 
reduced the risk of fatal plus nonfatal cerebrovascular events (stroke and transient ischemic 
attacks) by 28 %. There was no statistically significant difference between groups in non-
cardiovascular mortality.  
 
Primary Hypercholesterolaemia and Combined Hyperlipidaemia 
In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily in 
patients with hypercholesterolaemia, the mean reductions of LDL-C were 30, 38, 41 and 47%, 
respectively. In studies of patients with combined (mixed) hyperlipidaemia on simvastatin 40 
mg and 80 mg, the median reductions in triglycerides were 28 and 33 % (placebo: 2 %), 
respectively, and mean increases in HDL-C were 13 and 16 % (placebo: 3 %), respectively. 
 
5.2 Pharmacokinetic  properties 
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding 
beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Hydrolysis takes place mainly in 
the liver; the rate of hydrolysis in human plasma is very slow. 
 
Absorption 
In man simvastatin is well absorbed and undergoes extensive hepatic first –pass extraction. 
The extraction in the liver is dependant on the hepatic blood flow. The liver is the primary site 
of action of the active form. The availability of the beta-hydroxyacid to the systematic 
circulation following an oral dose of simvastatin was found to be less than 5 % of the dose. 
Maximum plasma concentration of active inhibitors is reached approximately 1-2 hours after 
administration of simvastatin. Concomitant food intake does not affect the absorption. 
 
The pharmacokinetics of single and multiple doses of simvastatin showed that no 
accumulation of medicinal product occurred after multiple dosing.  
 
Distribution 
The protein binding of simvastatin and its active metabolite is >95 %. 
 
Elimination 
Simvastatin is a substrate of CYP3A4 (see sections 4.3 and 4.5). The major metabolites of 
simvastatin present in human plasma are the beta-hydroxyacid and four additional active 
metabolites. Following an oral dose of radioactive simvastatin to man, 13 % of the 
radioactivity was excreted in the urine and 60 % in the faeces within 96 hours. The amount 
recovered in the faeces represents absorbed medicinal product equivalents excreted in bile as 
well as unabsorbed medicinal product. Following an intravenous injection of the beta-
hydroxyacid metabolite, its half-life averaged 1.9 hours. An average of only 0.3 % of the IV 
dose was excreted in urine as inhibitors.  
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5.3  Preclinical safety data 
Based on conventional animal studies regarding pharmacodynamics, repeated dose toxicity, 
genotoxicity and carcinogenicity, there are no other risks for the patient than may be expected 
on account of the pharmacological mechanism. At maximally tolerated doses in both the rat 
and the rabbit, simvastatin produced no foetal malformations, and had no effects on fertility, 
reproductive function or neonatal development.  
 
6 PHARMACEUTICAL  PARTICULARS 
6.1  List of excipients 
Lactose, anhydrous 
Cellulose, microcrystalline 
Maize starch, pregelatinised 
Butyl-hydroxyanisole (E320) 
Magnesium stearate 
Talc 
Hyprolose 
Hypromellose 
Titanium dioxide (E 171) 
 
6.2 Incompatibilities 
None. 
 
6.3 Shelf  life 
3 years 
 
6.4  Special precautions for storage 
Do not store above 25° C. Store in the original package. 
 
6.5  Nature and contents of container 
PVC/PE/PVDC/aluminium blisters- Each blister contains either 10 or 14 tablets to give pack 
sizes of 14, 28, 30, 56, 60 or 100 tablets, 
 
PVC/PE/PVDC/aluminium blisters in polyester/aluminium/PE sachets, - Each blister contains 
either 10 or 14 tablets. The blisters will be enclosed in a sachet to give pack sizes of 14, 28, 
30, 56, 60 or 100 tablets. These sachets will then be placed in an outer carton. 
 
HDPE container with child-proof PP closure and aluminium original seal. . The containers are 
available in pack sizes of 100’s and 500’s.  
 
Not all pack sizes may be marketed. 
 
6.6  Special precautions for disposal 
Not applicable 
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1  NAME OF THE MEDICINAL PRODUCT 
Simvastatin 20 mg Tablets 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each tablet contains 20mg of simvastatin 
For excipients, see 6.1 
 
3 PHARMACEUTICAL  FORM 
Film-coated tablets 
 
White, oblong, biconvex tablets, scored on one side, embossed with “20” on the scored side 
and with “SVT” on the opposite side. 
OR 
White oblong, biconvex tablets, scored on both sides, embossed with “SVT” and “20” on one 
side. 
 
4 CLINICAL  PARTICULARS 
4.1 Therapeutic  indications 
Hypercholesterolaemia 
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, 
when response to diet and other non-pharmacological treatments (e.g. exercise, weight 
reduction) is inadequate. 
 
Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-
lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. 
 
Cardiovascular prevention 
Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic 
cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, 
as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 
5.1). 
 
4.2  Posology and method of administration 
The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of 
dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 
80mg/day given as a single dose in the evening. The 80-mg dose is only recommended in 
patients with severe hypercholesterolaemia and high risk for cardiovascular complications. 
 
Hypercholestrolaemia 
The patient should be placed on a standard cholesterol-lowering diet, and should continue on 
this diet during treatment with Simvastatin tablets. The usual starting dose is 10-20mg/day 
given as a single dose in the evening. Patients who require a large reduction in LDL-C (more 
than 45%) may be started at 20-40 mg/day given as a single dose in the evening. Adjustments 
of dosage, if required, should be made as specified above. 
 
Homozygous familial hypercholesterolaemia 
Based on the results of a controlled clinical study, the recommended dosage is Simvastatin 
tablets 40mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an 
evening dose of 40 mg. Simvastatin tablets should be used as an adjunct to other lipid-
lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are 
unavailable.  
 
Cardiovascular prevention 
The usual dose of Simvastatin tablets is 20 to 40 mg/day given as a single dose in the evening 
in patients at high risk of coronary heart disease (CHD, with or without hyperlipidaemia). 
Drug therapy can be initiated simultaneously with diet and exercise. Adjustments of dosage, if 
required, should be made as specified above.  
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Concomitant therapy 
Simvastatin is effective alone or in combination with bile acid sequestrants. Dosing should 
occur either > 2 hours before or > 4 hours after administration of a bile acid sequestrant.  
 
In patients taking cyclosporine, danazol, gemfibrozil, other fibrates (except fenofibrate) or 
lipid-lowering doses (≥ 1g/day) of niacin concomitantly with ‘Simvastatin tablets’, the dose of 
‘Simvastatin tablets’ should not exceed 10 mg/day. In patients taking amiodarone or 
verapamil concomitantly with Simvastatin tablets, the dose of Simvastatin tablets should not 
exceed 20mg/day. (See sections 4.4 and 4.5)  
 
Dosage in renal insufficiency 
No modification of dosage should be necessary in patients with moderate renal insufficiency. 
In patients with severe renal insufficiency (creatinine clearance <30ml/min), dosages above 10 
mg/day should be carefully considered and, if deemed necessary, implemented cautiously.  
 
Use in the elderly 
No dosage adjustment is necessary 
 
Use in children and adolescents 
Efficacy and safety of use in children have not been established. Therefore Simvastatin  is not 
recommended for paediatric use. 
 
4.3 Contraindications 
•  Hypersensitivity to simvastatin or to any of the excipients 
•  Active liver disease or unexplained persistent elevations of serum transaminases 
•  Pregnancy and lactation (see section 4.6) 
•  Concomitant administration of potent CYP3A4 inhibitors (e.g itraconazole, ketoconazole, 
HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone) (see 
section 4.5). 
 
4.4  Special warnings and precautions for use 
Myopathy/Rhabdomyolysis 
Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes  myopathy 
manifested  as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times 
the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with 
or without acute renal failure secondary to myoglobinuria, and very rare fatalities have 
occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory 
activity in plasma. 
 
As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is dose 
related. In a clinical trial database in which 41,050 patients were treated with Simvastatin with 
24,747 (approximately 60 %) treated for at least 4 years, the incidence of myopathy was 
approximately 0.02 %, 0.08 % and 0.53 % at 20, 40 and 80 mg/day, respectively. In these 
trials, patients were carefully monitored and some interacting medicinal products were 
excluded.  
 
Creatine Kinase measurement  
Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence 
of any plausible alternative cause of CK increase as this makes value interpretation difficult. If 
CK levels are significantly elevated at baseline (>5 x ULN), levels should be re-measured 
within 5 to 7 days later to confirm the results. 
 
Before the treatment 
All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, 
should be advised of the risk of myopathy and told to report promptly any unexplained muscle 
pain, tenderness or weakness. 
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Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis. In 
order to establish a reference baseline value, a CK level should be measured before starting a 
treatment in the following situations:    
•  Elderly (age > 70 years) 
•  Renal impairment 
•  Uncontrolled hypothyroidism 
•  Personal or familial history of hereditary muscular disorders 
•  Previous history of muscular toxicity with a statin or fibrate 
•  Alcohol abuse 
 
In such situations, the risk of treatment should be considered in relation to possible benefit, 
and clinical monitoring is recommended. If a patient has previously experienced a muscle 
disorder on a fibrate or a statin, treatment with a different member of the class should only be 
initiated with caution. If CK levels are significantly elevated at baseline (>5 x ULN), 
treatment should not be started.  
 
Whilst on treatment  
If muscle pain, weakness or cramps occur whilst a patient is receiving treatment with a statin, 
their CK levels should be measured. If these levels are found, in the absence of strenuous 
exercise, to be significantly elevated (>5 x ULN), treatment should be stopped. If muscular 
symptoms are severe and cause daily discomfort, even if CK levels are <5 x ULN, treatment 
discontinuation may be considered. If myopathy is suspected for any other reason, treatment 
should be discontinued.  
 
If symptoms resolve and CK levels return to normal, then re-introduction of the statin or 
introduction of an alternative statin may be considered at the lowest dose and with close 
monitoring.  
 
Therapy with simvastatin should be temporarily stopped a few days prior to elective major 
surgery and when any major medical or surgical condition supervenes.  
 
Measures to reduce the risk of myopathy caused by medicinal product interactions (see also 
section 4.5)  
The risk of myopathy and rhabdomyolysis is significantly increased by concomitant use of 
simvastatin with potent inhibitors of CYP3A4 (such as itraconazole, ketoconazole, 
erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone), as well as 
gemfibrozil, ciclosporine and danazol (see section 4.2)  
 
The risk of myopathy and rhabdomyolysis is also increased by concomitant use of other 
fibrates, lipid-lowering doses (≥ 1 g/day) of niacin or by concomitant use of amiodarone or 
verapamil with higher doses of simvastatin (see sections 4.2 and 4.5). There is also a slight 
increase in risk when dilitiazem is used with simvastatin 80 mg.  
 
Consequently, regarding CYP3A4 inhibitors, the use of simvastatin concomitantly with 
itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin, 
telithromycin and nefazodone is contraindicated (see sections 4.3 and 4.5). If treatment with 
itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, 
therapy with simvastatin must be suspended during the course of treatment. Moreover, caution 
should be exercised when combining simvastatin with certain other less potent CYP3A4 
inhibitors: cyclosporine, verapamil, diltiazem (see sections 4.2 and 4.5). Concomitant intake 
of grapefruit juice and simvastatin should be avoided.  
 
The dose of simvastatin should not exceed 10mg daily in patients receiving concomitant 
medication with ciclosporine, danazol, gemfibrozil, or lipid-lowering doses (≥ 1 g/day) of 
niacin. The combined use of simvastatin with gemfibrozil should be avoided, unless the 
benefits are likely to outweigh the increased risks of this drug combination. The benefits of 
the combined use of simvastatin 10 mg daily with other fibrates (except fenofibrate), niacin or 
cyclosporine should be carefully weighed against the potential risks of these combinations. 
(See sections 4.2 and 4.5). 
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Caution should be used when prescribing fenofibrate with simvastatin, as either agent can 
cause myopathy when given alone.  
 
The combined use of simvastatin at doses higher than 20mg daily with amiodarone or 
verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk 
of myopathy (see sections 4.2 and 4.5). 
 
Hepatic effects 
In clinical studies, persistent increases (to > 3 x ULN) in serum transaminases have occurred 
in a few adult patients who received simvastatin. When simvastatin was interrupted or 
discontinued in these patients, the transaminase levels usually fell slowly to pre-treatment 
levels.  
 
It is recommended that liver function tests be performed before treatment begins and 
thereafter when clinically indicated. Patients titrated to the 80-mg dose should receive an 
additional test prior to titration, 3 months after titration to the 80-mg dose, and periodically 
thereafter (e.g. semi-annually) for the first year of treatment. Special attention should be paid 
to patients who develop elevated serum transaminase levels, and in these patients, 
measurements should be repeated promptly and then performed more frequently. If the 
transaminase levels show evidence of progression, particularly if they rise to 3 x ULN and are 
persistent, simvastatin should be discontinued.  
 
The product should be used with caution in patients who consume substantial quantities of 
alcohol.  
 
As with other lipid-lowering agents, moderate (<3 x ULN) elevations of serum transaminases 
have been reported following therapy with simvastatin. These changes appeared soon after 
initiation of therapy with simvastatin, were often transient, were not accompanied by any 
symptoms and interruption of treatment was not required. 
 
Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase 
deficiency or glucose-galactose malabsorption should not take this medicine. 
 
4.5  Interaction with other medicinal products and other forms of interaction 
Pharmacodynamic interactions 
Interactions with lipid-lowering medicinal products that can cause myopathy when given 
alone 
The risk of myopathy, including rhabdomyolysis, is increased during concomitant 
administration with fibrates and niacin (nicotinic acid) (≥ 1 g/day). Additionally, there is a 
pharmacokinetic interaction with gemfibrozil resulting in increased simvastatin plasma levels 
(see Pharmacokinetic interactions and sections 4.2 and 4.4). When simvastatin and fenofibrate 
are given concomitantly, there is no evidence that the risk of myopathy exceeds the sum of the 
individual risks of each agent. Adequate pharmacovigilance and pharmacokinetic data are not 
available for other fibrates.  
 
Pharmacokinetic interactions 
Prescribing recommendations for interacting agents are summarized in the table below 
(further details are provided in the text; see also sections 4.2, 4.3, and 4.4). 
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Drug Interactions Associated with Increased  
Risk of Myopathy/Rhabdomyolysis 
Interacting agents  Prescribing recommendations 
Potent CYP3A4 inhibitors: 
Itraconazole 
Ketoconazole 
Erythromycin 
Clarithromycin 
Telithromycin 
HIV protease inhibitors 
Nefazodone 
 
Contraindicated with simvastatin 
Gemfibrozil  Avoid but if necessary, do not exceed 10 mg simvastatin 
daily 
Ciclosporin 
Danazol 
Other fibrates (except 
fenofibrate) 
Niacin (≥1 g/day) 
Do not exceed 10 mg simvastatin daily 
Amiodarone 
Verapamil 
Do not exceed 20 mg simvastatin daily 
Diltiazem  Do not exceed 40 mg simvastatin daily 
Grapefruit juice  Avoid grapefruit juice when taking simvastatin 
 
Effects of other medicinal products on simvastatin  
Interactions involving CYP3A4 
Simvastatin is a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome P450 
3A4 increase the risk of myopathy and rhabdomyolysis by increasing the concentration of 
HMG-CoA reductase inhibitory activity in plasma during simvastatin therapy. Such inhibitors 
include itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease 
inhibitors, and nefazodone. Concomitant administration of itraconazole resulted in a more 
than 10-fold increase in exposure to simvastatin acid (the active beta-hydroxyacid metabolite). 
Telithromycin caused an 11-fold increase in exposure to simvastatin acid.  
 
Therefore, combination with itraconazole, ketoconazole, HIV protease inhibitors, 
erythromycin, clarithromycin, telithromycin and nefazodone is contraindicated. If treatment 
with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is 
unavoidable, therapy with simvastatin must be suspended during the course of treatment. 
Caution should be exercised when combining simvastatin with certain other less potent 
CYP3A4 inhibitors: ciclosporine, verapamil, dilitiazem (see sections 4.2 and 4.4). 
 
Ciclosporine 
The risk of myopathy/rhabdomyolysis is increased by concomitant administration of 
ciclosporine particularly with higher doses of simvastatin (see sections 4.2 and 4.4). 
Therefore, the dose of simvastatin should not exceed 10 mg daily in patients receiving 
concomitant medication with cyclosporine. Although the mechanism is not fully understood, 
ciclosporine has been shown to increase the AUC HMG-CoA reductase inhibitors. The 
increase in AUC of simvastatin acid presumably due, in part, to inhibition of CYP3A4.    
 
Danazol 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
danazol with higher doses of simvastatin (see sections 4.2 and 4.4). 
 
Gemfibrozil 
Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of 
the glucuronidation pathway (see sections 4.2 and 4.4). 
 
Amiodarone and verapamil 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
amiodarone or verapamil with higher doses of simvastatin (see section 4.4). In an ongoing 
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clinical trial, myopathy has been reported in 6% of patients receiving simvastatin 80 mg and 
amiodarone. 
 
An analysis of the available clinical trials showed an approximately 1 % incidence of 
myopathy in patients receiving simvastatin 40mg or 80 mg and verapamil. In a 
pharmacokinetic study, concomitant administration with verapamil resulted in a 2.3-fold 
increase in exposure of simvastatin acid, presumably due, in part, to inhibition of CYP3A4. 
Therefore, the dose of simvastatin should not exceed 20mg daily in patients receiving 
concomitant medication with amiodarone or verapamil, unless the clinical benefit is likely to 
outweigh the increased risk of myopathy and rhabdomyolysis. 
 
Diltiazem 
An analysis of the available clinical trials showed a 1 % incidence of myopathy in patients 
receiving simvastatin 80mg and diltiazem. The risk of myopathy in patients taking simvastatin 
40 mg was not increased by concomitant diltiazem (see section 4.4). In a pharmacokinetic 
study, concomitant administration of diltiazem caused a 2.7-fold increase in exposure of 
simvastatin acid, presumably due to inhibition of CYP3A4. Therefore, the dose of simvastatin 
should not exceed 40 mg daily in patients receiving concomitant medication with diltiazem, 
unless the clinical benefit is likely to outweigh the increased risk of myopathy and 
rhabdomyolysis.  
 
Grapefruit juice 
Grapefruit juice inhibits cytochrome P450 3A4. Concomitant intake of large quantities (over 1 
litre daily) of grapefruit juice and simvastatin resulted in a 7-fold increase in exposure to 
simvastatin acid. Intake of 240 ml of grapefruit juice in the morning and simvastatin in the 
evening also resulted in a 1.9-fold increase. Intake of grapefruit juice during treatment with 
simvastatin should therefore be avoided.  
 
Effects of simvastatin on the pharmacokinetics of other medicinal products 
Simvastatin does not have an inhibitory effect on cytochrome P450 3A4. Therefore, 
simvastatin is not expected to affect plasma concentrations of substances metabolised via 
cytochrome P450 3A4. 
 
Oral anticoagulants 
In two clinical studies, one in normal volunteers and the other in hypercholesterolaemic 
patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin 
anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), 
increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, 
respectively. Very rare cases of elevated INR have been reported. In patients taking coumarin 
anticoagulants, prothrombin time should be determined before starting simvastatin and 
frequently enough during early therapy to ensure that no significant alteration of prothrombin 
time occurs. Once a stable prothrombin time has been documented, prothrombin times can be 
monitored at the intervals usually recommended for patients on coumarin anticoagulants. If 
the dose of simvastatin is changed or discontinued, the same procedure should be repeated. 
Simvastatin therapy has not been associated with bleeding or with changes in prothrombin 
time in patients not taking anticoagulants.  
 
4.6 Pregnancy  and  lactation 
Pregnancy 
Simvastatin is contraindicated during pregnancy (see section 4.3). 
 
Safety in pregnant women has not been established. No controlled clinical trials with 
simvastatin have been conducted in pregnant women. Rare reports of congenital anomalies 
following intrauterine exposure to HMG-CoA reductase inhibitors have been received. 
However, in an analysis of approximately 200 prospectively followed pregnancies exposed 
during the first trimester to simvastatin or another closely related HMG-CoA reductase 
inhibitor, the incidence of congenital anomalies was comparable to that seen in the general 
population. This number of pregnancies was statistically sufficient to exclude a 2.5-fold or 
greater increase in congenital anomalies over the background incidence.  
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Although there is no evidence that the incidence of congenital anomalies in offspring of 
patients taking simvastatin or another closely related HMG-CoA reductase inhibitor differs 
from that observed in the general population, maternal treatment with simvastatin  may reduce 
the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis. 
Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering 
medicinal products during pregnancy should have little impact on the long-term risk 
associated with primary hypercholesterolaemia. For these reasons, simvastatin should not be 
used in women who are pregnant, trying to become pregnant or suspect they are pregnant. 
Treatment with simvastatin should be suspended for the duration of pregnancy or until it has 
been determined that the woman is not pregnant. (See section 4.3). 
 
Lactation 
It is not known whether simvastatin or its metabolites are excreted in human milk. Because 
many medicinal products are excreted in human milk and because of the potential for serious 
adverse reactions, women taking simvastatin should not breast-feed their infants (see section 
4.3). 
 
4.7  Effects on ability to drive and use machines 
Simvastatin has no or negligible influence on the ability to drive and use machines.  
 
However, when driving vehicles or operating machines, it should be taken into account that 
dizziness has been reported rarely in post-marketing experiences. 
 
4.8 Undesirable  effects 
 The frequencies of the following adverse events, which have been reported during clinical 
studies and/or post-marketing use, are categorized based on an assessment of their incidence 
rates in large, long-term, placebo-controlled, clinical trials including HPS and 4S with 20,536 
and 4,444 patients, respectively (see section 5.1). For HPS, only serious adverse events were 
recorded as well as myalgia, increases in serum transaminases and CK. For 4S, all the adverse 
events listed below were recorded. If the incidence rates on simvastatin were less than or 
similar to that of placebo in these trials, and there were similar reasonably causally related 
spontaneous report events, these adverse events are categorized as ‘rare’.  
 
In HPS (see section 5.1) involving 20,536 patients treated with 40mg/day of simvastatin 
(n=10,269) or placebo (n=10,267), the safety profiles were comparable between patients 
treated with simvastatin  40 mg and patients treated with placebo over the mean 5 years of the 
study. Discontinuation rates due to side effects were comparable (4.8 % in patients treated 
with simvastatin 40mg compared with 5.1% in patients treated with placebo). The incidence 
of myopathy was <0.1% in patients treated with simvastatin  40 mg. Elevated transaminases 
(>3 x ULN confirmed by repeat test) occurred in 0.21 % (n=21) of patients treated with 
simvastatin 40mg compared with 0.09% (n = 9) of patients treated with placebo.  
 
The frequencies of adverse events are ranked according to the following: Very common (> 
1/10), Common (≥ 1/100, <1/10), Uncommon (≥ 1/1000, <1/100), Rare (≥ 1/10,000, 
<1/1000), Very Rare (<1/10,000) including isolated reports.  
 
Blood and lymphatic system disorders:  
Rare: anaemia 
 
Nervous system disorders:  
Rare: headache, paresthesia, dizziness, peripheral neuropathy 
 
Gastrointestinal disorders: 
Rare: constipation, abdominal pain, flatulence, dyspepsia, diarrhoea, nausea, vomiting, 
pancreatitis 
 
Hepato-biliary disorders: 
Rare: hepatitis/jaundice 
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Skin and subcutaneous tissue disorders: 
Rare: rash, pruritus, alopecia 
 
Musculoskeletal, connective tissue and bone disorders: 
Rare: myopathy, rhabdomyolysis (see section 4.4), myalgia, muscle cramps 
General disorders and administration site conditions:  
Rare: asthenia  
 
An apparent hypersensitivity syndrome has been reported rarely which has included some of 
the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, 
dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis and 
arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise. 
 
Investigations: 
Rare: increases in serum transaminases (alanine aminotransferase, aspartate aminotransferase, 
γ-glutamyl transpeptidase) (see section 4.4 Hepatic effects), elevated alkaline phosphatase; 
increase in serum CK levels (see section 4.4). 
 
4.9 Overdose 
To date, a few cases of overdosage have been reported; the maximum dose was 3.6 g. All 
patients recovered without sequelae. There is no specific treatment in the event of overdose. In 
this case, symptomatic and supportive measures should be adopted. 
 
5 PHARMACOLOGICAL  PROPERTIES 
5.1 Pharmacodynamic  properties 
Pharmacotherapeutic group: HMG-CoA reductase inhibitor 
ATC-Code: C10A A01 
 
After oral ingestion, simvastatin, which is an active lactone, is hydrolyzed in the liver to the 
corresponding active beta-hydroxyacid form which has a potent activity in inhibiting HMG-
CoA reductase (3 hydroxy – 3 methylglutaryly CoA reductase). This enzyme catalyses the 
conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthesis of 
cholesterol.  
 
Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations. LDL 
is formed from very-low-density protein (VLDL) and is catabolised predominantly by the 
high affinity LDL receptor. The mechanism of the LDL-lowering effect of ‘Simvastatin 
tablets’ may involve both reduction of VLDL-chlolestrol (VLDL-C) concentration and 
induction of the LDL receptor, leading to reduced production and increased catabolism of 
LDL-C. Apolipoprotein B also falls substantially during treatment with ‘Simvastatin tablets’. 
In addition, ‘Simvastatin tablets’ moderately increases HDL-C and reduces plasma TG. As a 
result of these changes the ratios of total to HDL-C and LDL-to HDL-C are reduced. 
 
High Risk of Coronary Heart Disease (CHD) or Existing Coronary Heart Disease 
In the Heart Protection Study (HPS), the effects of therapy with Simvastatin tablets were 
assessed in 20,536 patients (age 40-48 years), with or without hyperlipidaemia, and with 
coronary heart disease, other occlusive arterial disease or diabetes mellitus. In this study, 
10,269 patients were treated with simvastatin tablets 40mg/day and 10,267 patients were 
treated with placebo for a mean duration of 5 years. At baseline, 6,793 patients (33 %) had 
LDL-C levels below 116 mg/dL; 5,063 patients (25 %) had levels between 116 mg/dL and 
135mg/dL; and 8,680 patients (42 %) had levels greater than 135 mg/dL. 
 
Treatment with Simvastatin tablets 40 mg/day compared with placebo significantly reduced 
the risk of all cause mortality (1328 [12.9%] for simvastatin-treated patients versus 1507 [14.7 
%] for patients given placebo; p=0.0003), due to an 18% reduction in coronary death rate (587 
[5.7 %] versus 707 [6.9 %]; p=0.0005; absolute risk reduction of 1.2 %). The reduction in 
non-vascular deaths did not reach statistical significance. ‘Simvastatin tablets’ also decreased 
the risk of major coronary events (a composite endpoint comprised of non-fatal MI or CHD 
death) by 27 % (p<0.0001). Simvastatin tablets reduced the need for undergoing coronary 
revascularization procedures (including coronary artery bypass grafting or percutaneous 
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transluminal coronary angioplasty) and peripheral and other non-coronary revascularization 
procedures by 30 % (p<0.0001) and 16 % (p = 0.006), respectively. Simvastatin tablets 
reduced the risk of stroke by 25 % (p<0.0001), attributable to a 30 % reduction in ischemic 
stroke (p<0.0001). In addition, within the subgroup of patients with diabetes, simvastatin 
tablets reduced the risk of developing macrovascular complications, including peripheral 
revascularization procedures (surgery or angioplasty), lower limb amputations, or leg ulcers 
by 21 % (p = 0.0293). The proportional reduction in event rate was similar in each subgroup 
of patients studied, including those without coronary disease but who had cerebrovascular or 
peripheral artery disease, men and women, those aged either under or over 70 years at entry 
into study, presence or absence of hypertension, and notably those with LDL cholesterol 
below 3.0 mmol/l at inclusion.  
 
In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with simvastatin on 
total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 
mg/dL (5.5-8.0 mmol/L). In this multicenter, randomised, double-blind, placebo controlled 
study, patients with angina or a previous myocardial infarction (MI) were treated with diet, 
standard care, and either simvastatin  20-40 mg/day (n = 2,221) or placebo (n=2,223) for a 
median duration of 5.4 years. Simvastatin tablets reduced the risk of death by 30 % (absolute 
risk reduction of 3.3 %). The risk of CHD death was reduced by 42 % (absolute risk reduction 
of 3.5 %). Simvastatin also decreased the risk of having major coronary events (CHD death 
plus hospital-verified and silent nonfatal MI) by 34 %. Furthermore, simvastatin significantly 
reduced the risk of fatal plus nonfatal cerebrovascular events (stroke and transient ischemic 
attacks) by 28 %. There was no statistically significant difference between groups in non-
cardiovascular mortality.  
 
Primary Hypercholesterolaemia and Combined Hyperlipidaemia 
In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily in 
patients with hypercholesterolaemia, the mean reductions of LDL-C were 30, 38, 41 and 47%, 
respectively. In studies of patients with combined (mixed) hyperlipidaemia on simvastatin 40 
mg and 80 mg, the median reductions in triglycerides were 28 and 33 % (placebo: 2 %), 
respectively, and mean increases in HDL-C were 13 and 16 % (placebo: 3 %), respectively. 
 
5.2 Pharmacokinetic  properties 
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding 
beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Hydrolysis takes place mainly in 
the liver; the rate of hydrolysis in human plasma is very slow. 
 
Absorption 
In man simvastatin is well absorbed and undergoes extensive hepatic first –pass extraction. 
The extraction in the liver is dependant on the hepatic blood flow. The liver is the primary site 
of action of the active form. The availability of the beta-hydroxyacid to the systematic 
circulation following an oral dose of simvastatin was found to be less than 5 % of the dose. 
Maximum plasma concentration of active inhibitors is reached approximately 1-2 hours after 
administration of simvastatin. Concomitant food intake does not affect the absorption. 
 
The pharmacokinetics of single and multiple doses of simvastatin showed that no 
accumulation of medicinal product occurred after multiple dosing.  
 
Distribution 
The protein binding of simvastatin and its active metabolite is >95 %. 
 
Elimination 
Simvastatin is a substrate of CYP3A4 (see sections 4.3 and 4.5). The major metabolites of 
simvastatin present in human plasma are the beta-hydroxyacid and four additional active 
metabolites. Following an oral dose of radioactive simvastatin to man, 13 % of the 
radioactivity was excreted in the urine and 60 % in the faeces within 96 hours. The amount 
recovered in the faeces represents absorbed medicinal product equivalents excreted in bile as 
well as unabsorbed medicinal product. Following an intravenous injection of the beta-
hydroxyacid metabolite, its half-life averaged 1.9 hours. An average of only 0.3 % of the IV 
dose was excreted in urine as inhibitors.  
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5.3  Preclinical safety data 
Based on conventional animal studies regarding pharmacodynamics, repeated dose toxicity, 
genotoxicity and carcinogenicity, there are no other risks for the patient than may be expected 
on account of the pharmacological mechanism. At maximally tolerated doses in both the rat 
and the rabbit, simvastatin produced no foetal malformations, and had no effects on fertility, 
reproductive function or neonatal development.  
 
6 PHARMACEUTICAL  PARTICULARS 
6.1  List of excipients 
Lactose, anhydrous 
Cellulose, microcrystalline 
Maize starch, pregelatinised 
Butyl-hydroxyanisole (E320) 
Magnesium stearate 
Talc 
Hyprolose 
Hypromellose 
Titanium dioxide (E 171) 
 
6.2 Incompatibilities 
None. 
 
6.3 Shelf  life 
3 years 
 
6.4  Special precautions for storage 
Do not store above 25° C. Store in the original package. 
 
6.5  Nature and contents of container 
PVC/PE/PVDC/aluminium blisters- Each blister contains either 10 or 14 tablets to give pack 
sizes of 14, 28, 30, 56, 60 or 100 tablets, 
 
PVC/PE/PVDC/aluminium blisters in polyester/aluminium/PE sachets, - Each blister contains 
either 10 or 14 tablets. The blisters will be enclosed in a sachet to give pack sizes of 14, 28, 
30, 56, 60 or 100 tablets. These sachets will then be placed in an outer carton. 
 
HDPE container with child-proof PP closure and aluminium original seal. . The containers are 
available in pack sizes of 100’s and 500’s.  
 
Not all pack sizes may be marketed. 
 
6.6  Special precautions for disposal 
Not applicable 
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1  NAME OF THE MEDICINAL PRODUCT 
Simvastatin 40 mg Tablets 
 
2  QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each tablet contains 40mg of simvastatin 
For excipients, see 6.1 
 
3 PHARMACEUTICAL  FORM 
Film-coated tablets 
 
White, oblong, biconvex tablets, scored on one side, embossed with “40” on the scored side 
and with “SVT” on the opposite side. 
OR 
White oblong, biconvex tablets, scored on both sides, embossed with “SVT” and “40” on one 
side. 
 
4 CLINICAL  PARTICULARS 
4.1 Therapeutic  indications 
Hypercholesterolaemia 
Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, 
when response to diet and other non-pharmacological treatments (e.g. exercise, weight 
reduction) is inadequate. 
 
Treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-
lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate. 
 
Cardiovascular prevention 
Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic 
cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, 
as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 
5.1). 
 
4.2  Posology and method of administration 
The dosage range is 5-80 mg/day given orally as a single dose in the evening. Adjustments of 
dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 
80mg/day given as a single dose in the evening. The 80-mg dose is only recommended in 
patients with severe hypercholesterolaemia and high risk for cardiovascular complications. 
 
Hypercholestrolaemia 
The patient should be placed on a standard cholesterol-lowering diet, and should continue on 
this diet during treatment with Simvastatin tablets. The usual starting dose is 10-20mg/day 
given as a single dose in the evening. Patients who require a large reduction in LDL-C (more 
than 45%) may be started at 20-40 mg/day given as a single dose in the evening. Adjustments 
of dosage, if required, should be made as specified above. 
 
Homozygous familial hypercholesterolaemia 
Based on the results of a controlled clinical study, the recommended dosage is Simvastatin 
tablets 40mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an 
evening dose of 40 mg. Simvastatin tablets should be used as an adjunct to other lipid-
lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are 
unavailable.  
 
Cardiovascular prevention 
The usual dose of Simvastatin tablets is 20 to 40 mg/day given as a single dose in the evening 
in patients at high risk of coronary heart disease (CHD, with or without hyperlipidaemia). 
Drug therapy can be initiated simultaneously with diet and exercise. Adjustments of dosage, if 
required, should be made as specified above.  
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Concomitant therapy 
Simvastatin is effective alone or in combination with bile acid sequestrants. Dosing should 
occur either > 2 hours before or > 4 hours after administration of a bile acid sequestrant.  
 
In patients taking cyclosporine, danazol, gemfibrozil, other fibrates (except fenofibrate) or 
lipid-lowering doses (≥ 1g/day) of niacin concomitantly with ‘Simvastatin tablets’, the dose of 
‘Simvastatin tablets’ should not exceed 10 mg/day. In patients taking amiodarone or 
verapamil concomitantly with Simvastatin tablets, the dose of Simvastatin tablets should not 
exceed 20mg/day. (See sections 4.4 and 4.5)  
 
Dosage in renal insufficiency 
No modification of dosage should be necessary in patients with moderate renal insufficiency. 
In patients with severe renal insufficiency (creatinine clearance <30ml/min), dosages above 10 
mg/day should be carefully considered and, if deemed necessary, implemented cautiously.  
 
Use in the elderly 
No dosage adjustment is necessary 
 
Use in children and adolescents 
Efficacy and safety of use in children have not been established. Therefore Simvastatin  is not 
recommended for paediatric use. 
 
4.3 Contraindications 
•  Hypersensitivity to simvastatin or to any of the excipients 
•  Active liver disease or unexplained persistent elevations of serum transaminases 
•  Pregnancy and lactation (see section 4.6) 
•  Concomitant administration of potent CYP3A4 inhibitors (e.g itraconazole, ketoconazole, 
HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone) (see 
section 4.5). 
 
4.4  Special warnings and precautions for use 
Myopathy/Rhabdomyolysis 
Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes  myopathy 
manifested  as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times 
the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with 
or without acute renal failure secondary to myoglobinuria, and very rare fatalities have 
occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory 
activity in plasma. 
 
As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is dose 
related. In a clinical trial database in which 41,050 patients were treated with Simvastatin with 
24,747 (approximately 60 %) treated for at least 4 years, the incidence of myopathy was 
approximately 0.02 %, 0.08 % and 0.53 % at 20, 40 and 80 mg/day, respectively. In these 
trials, patients were carefully monitored and some interacting medicinal products were 
excluded.  
 
Creatine Kinase measurement  
Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence 
of any plausible alternative cause of CK increase as this makes value interpretation difficult. If 
CK levels are significantly elevated at baseline (>5 x ULN), levels should be re-measured 
within 5 to 7 days later to confirm the results. 
 
Before the treatment 
All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, 
should be advised of the risk of myopathy and told to report promptly any unexplained muscle 
pain, tenderness or weakness. 
 
Caution should be exercised in patients with pre-disposing factors for rhabdomyolysis. In 
order to establish a reference baseline value, a CK level should be measured before starting a 
treatment in the following situations:    
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•  Elderly (age > 70 years) 
•  Renal impairment 
•  Uncontrolled hypothyroidism 
•  Personal or familial history of hereditary muscular disorders 
•  Previous history of muscular toxicity with a statin or fibrate 
•  Alcohol abuse 
 
In such situations, the risk of treatment should be considered in relation to possible benefit, 
and clinical monitoring is recommended. If a patient has previously experienced a muscle 
disorder on a fibrate or a statin, treatment with a different member of the class should only be 
initiated with caution. If CK levels are significantly elevated at baseline (>5 x ULN), 
treatment should not be started.  
 
Whilst on treatment  
If muscle pain, weakness or cramps occur whilst a patient is receiving treatment with a statin, 
their CK levels should be measured. If these levels are found, in the absence of strenuous 
exercise, to be significantly elevated (>5 x ULN), treatment should be stopped. If muscular 
symptoms are severe and cause daily discomfort, even if CK levels are <5 x ULN, treatment 
discontinuation may be considered. If myopathy is suspected for any other reason, treatment 
should be discontinued.  
 
If symptoms resolve and CK levels return to normal, then re-introduction of the statin or 
introduction of an alternative statin may be considered at the lowest dose and with close 
monitoring.  
 
Therapy with simvastatin should be temporarily stopped a few days prior to elective major 
surgery and when any major medical or surgical condition supervenes.  
 
Measures to reduce the risk of myopathy caused by medicinal product interactions (see also 
section 4.5)  
The risk of myopathy and rhabdomyolysis is significantly increased by concomitant use of 
simvastatin with potent inhibitors of CYP3A4 (such as itraconazole, ketoconazole, 
erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone), as well as 
gemfibrozil, ciclosporine and danazol (see section 4.2)  
 
The risk of myopathy and rhabdomyolysis is also increased by concomitant use of other 
fibrates, lipid-lowering doses (≥ 1 g/day) of niacin or by concomitant use of amiodarone or 
verapamil with higher doses of simvastatin (see sections 4.2 and 4.5). There is also a slight 
increase in risk when dilitiazem is used with simvastatin 80 mg.  
 
Consequently, regarding CYP3A4 inhibitors, the use of simvastatin concomitantly with 
itraconazole, ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin, 
telithromycin and nefazodone is contraindicated (see sections 4.3 and 4.5). If treatment with 
itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, 
therapy with simvastatin must be suspended during the course of treatment. Moreover, caution 
should be exercised when combining simvastatin with certain other less potent CYP3A4 
inhibitors: cyclosporine, verapamil, diltiazem (see sections 4.2 and 4.5). Concomitant intake 
of grapefruit juice and simvastatin should be avoided.  
 
The dose of simvastatin should not exceed 10mg daily in patients receiving concomitant 
medication with ciclosporine, danazol, gemfibrozil, or lipid-lowering doses (≥ 1 g/day) of 
niacin. The combined use of simvastatin with gemfibrozil should be avoided, unless the 
benefits are likely to outweigh the increased risks of this drug combination. The benefits of 
the combined use of simvastatin 10 mg daily with other fibrates (except fenofibrate), niacin or 
cyclosporine should be carefully weighed against the potential risks of these combinations. 
(See sections 4.2 and 4.5). 
 
Caution should be used when prescribing fenofibrate with simvastatin, as either agent can 
cause myopathy when given alone.  
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The combined use of simvastatin at doses higher than 20mg daily with amiodarone or 
verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk 
of myopathy (see sections 4.2 and 4.5). 
 
Hepatic effects 
In clinical studies, persistent increases (to > 3 x ULN) in serum transaminases have occurred 
in a few adult patients who received simvastatin. When simvastatin was interrupted or 
discontinued in these patients, the transaminase levels usually fell slowly to pre-treatment 
levels.  
 
It is recommended that liver function tests be performed before treatment begins and 
thereafter when clinically indicated. Patients titrated to the 80-mg dose should receive an 
additional test prior to titration, 3 months after titration to the 80-mg dose, and periodically 
thereafter (e.g. semi-annually) for the first year of treatment. Special attention should be paid 
to patients who develop elevated serum transaminase levels, and in these patients, 
measurements should be repeated promptly and then performed more frequently. If the 
transaminase levels show evidence of progression, particularly if they rise to 3 x ULN and are 
persistent, simvastatin should be discontinued.  
 
The product should be used with caution in patients who consume substantial quantities of 
alcohol.  
 
As with other lipid-lowering agents, moderate (<3 x ULN) elevations of serum transaminases 
have been reported following therapy with simvastatin. These changes appeared soon after 
initiation of therapy with simvastatin, were often transient, were not accompanied by any 
symptoms and interruption of treatment was not required. 
 
Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase 
deficiency or glucose-galactose malabsorption should not take this medicine. 
 
4.5  Interaction with other medicinal products and other forms of interaction 
Pharmacodynamic interactions 
Interactions with lipid-lowering medicinal products that can cause myopathy when given 
alone 
The risk of myopathy, including rhabdomyolysis, is increased during concomitant 
administration with fibrates and niacin (nicotinic acid) (≥ 1 g/day). Additionally, there is a 
pharmacokinetic interaction with gemfibrozil resulting in increased simvastatin plasma levels 
(see Pharmacokinetic interactions and sections 4.2 and 4.4). When simvastatin and fenofibrate 
are given concomitantly, there is no evidence that the risk of myopathy exceeds the sum of the 
individual risks of each agent. Adequate pharmacovigilance and pharmacokinetic data are not 
available for other fibrates.  
 
Pharmacokinetic interactions 
Prescribing recommendations for interacting agents are summarized in the table below 
(further details are provided in the text; see also sections 4.2, 4.3, and 4.4). 
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Drug Interactions Associated with Increased  
Risk of Myopathy/Rhabdomyolysis 
Interacting agents  Prescribing recommendations 
Potent CYP3A4 inhibitors: 
Itraconazole 
Ketoconazole 
Erythromycin 
Clarithromycin 
Telithromycin 
HIV protease inhibitors 
Nefazodone 
 
Contraindicated with simvastatin 
Gemfibrozil  Avoid but if necessary, do not exceed 10 mg simvastatin 
daily 
Ciclosporin 
Danazol 
Other fibrates (except 
fenofibrate) 
Niacin (≥1 g/day) 
Do not exceed 10 mg simvastatin daily 
Amiodarone 
Verapamil 
Do not exceed 20 mg simvastatin daily 
Diltiazem  Do not exceed 40 mg simvastatin daily 
Grapefruit juice  Avoid grapefruit juice when taking simvastatin 
 
Effects of other medicinal products on simvastatin  
Interactions involving CYP3A4 
Simvastatin is a substrate of cytochrome P450 3A4. Potent inhibitors of cytochrome P450 
3A4 increase the risk of myopathy and rhabdomyolysis by increasing the concentration of 
HMG-CoA reductase inhibitory activity in plasma during simvastatin therapy. Such inhibitors 
include itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease 
inhibitors, and nefazodone. Concomitant administration of itraconazole resulted in a more 
than 10-fold increase in exposure to simvastatin acid (the active beta-hydroxyacid metabolite). 
Telithromycin caused an 11-fold increase in exposure to simvastatin acid.  
 
Therefore, combination with itraconazole, ketoconazole, HIV protease inhibitors, 
erythromycin, clarithromycin, telithromycin and nefazodone is contraindicated. If treatment 
with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is 
unavoidable, therapy with simvastatin must be suspended during the course of treatment. 
Caution should be exercised when combining simvastatin with certain other less potent 
CYP3A4 inhibitors: ciclosporine, verapamil, dilitiazem (see sections 4.2 and 4.4). 
 
Ciclosporine 
The risk of myopathy/rhabdomyolysis is increased by concomitant administration of 
ciclosporine particularly with higher doses of simvastatin (see sections 4.2 and 4.4). 
Therefore, the dose of simvastatin should not exceed 10 mg daily in patients receiving 
concomitant medication with cyclosporine. Although the mechanism is not fully understood, 
ciclosporine has been shown to increase the AUC HMG-CoA reductase inhibitors. The 
increase in AUC of simvastatin acid presumably due, in part, to inhibition of CYP3A4.    
 
Danazol 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
danazol with higher doses of simvastatin (see sections 4.2 and 4.4). 
 
Gemfibrozil 
Gemfibrozil increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of 
the glucuronidation pathway (see sections 4.2 and 4.4). 
 
Amiodarone and verapamil 
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of 
amiodarone or verapamil with higher doses of simvastatin (see section 4.4). In an ongoing 
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clinical trial, myopathy has been reported in 6% of patients receiving simvastatin 80 mg and 
amiodarone. 
 
An analysis of the available clinical trials showed an approximately 1 % incidence of 
myopathy in patients receiving simvastatin 40mg or 80 mg and verapamil. In a 
pharmacokinetic study, concomitant administration with verapamil resulted in a 2.3-fold 
increase in exposure of simvastatin acid, presumably due, in part, to inhibition of CYP3A4. 
Therefore, the dose of simvastatin should not exceed 20mg daily in patients receiving 
concomitant medication with amiodarone or verapamil, unless the clinical benefit is likely to 
outweigh the increased risk of myopathy and rhabdomyolysis. 
 
Diltiazem 
An analysis of the available clinical trials showed a 1 % incidence of myopathy in patients 
receiving simvastatin 80mg and diltiazem. The risk of myopathy in patients taking simvastatin 
40 mg was not increased by concomitant diltiazem (see section 4.4). In a pharmacokinetic 
study, concomitant administration of diltiazem caused a 2.7-fold increase in exposure of 
simvastatin acid, presumably due to inhibition of CYP3A4. Therefore, the dose of simvastatin 
should not exceed 40 mg daily in patients receiving concomitant medication with diltiazem, 
unless the clinical benefit is likely to outweigh the increased risk of myopathy and 
rhabdomyolysis.  
 
Grapefruit juice 
Grapefruit juice inhibits cytochrome P450 3A4. Concomitant intake of large quantities (over 1 
litre daily) of grapefruit juice and simvastatin resulted in a 7-fold increase in exposure to 
simvastatin acid. Intake of 240 ml of grapefruit juice in the morning and simvastatin in the 
evening also resulted in a 1.9-fold increase. Intake of grapefruit juice during treatment with 
simvastatin should therefore be avoided.  
 
Effects of simvastatin on the pharmacokinetics of other medicinal products 
Simvastatin does not have an inhibitory effect on cytochrome P450 3A4. Therefore, 
simvastatin is not expected to affect plasma concentrations of substances metabolised via 
cytochrome P450 3A4. 
 
Oral anticoagulants 
In two clinical studies, one in normal volunteers and the other in hypercholesterolaemic 
patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin 
anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), 
increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, 
respectively. Very rare cases of elevated INR have been reported. In patients taking coumarin 
anticoagulants, prothrombin time should be determined before starting simvastatin and 
frequently enough during early therapy to ensure that no significant alteration of prothrombin 
time occurs. Once a stable prothrombin time has been documented, prothrombin times can be 
monitored at the intervals usually recommended for patients on coumarin anticoagulants. If 
the dose of simvastatin is changed or discontinued, the same procedure should be repeated. 
Simvastatin therapy has not been associated with bleeding or with changes in prothrombin 
time in patients not taking anticoagulants.  
 
4.6 Pregnancy  and  lactation 
Pregnancy 
Simvastatin is contraindicated during pregnancy (see section 4.3). 
 
Safety in pregnant women has not been established. No controlled clinical trials with 
simvastatin have been conducted in pregnant women. Rare reports of congenital anomalies 
following intrauterine exposure to HMG-CoA reductase inhibitors have been received. 
However, in an analysis of approximately 200 prospectively followed pregnancies exposed 
during the first trimester to simvastatin or another closely related HMG-CoA reductase 
inhibitor, the incidence of congenital anomalies was comparable to that seen in the general 
population. This number of pregnancies was statistically sufficient to exclude a 2.5-fold or 
greater increase in congenital anomalies over the background incidence.  
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Although there is no evidence that the incidence of congenital anomalies in offspring of 
patients taking simvastatin or another closely related HMG-CoA reductase inhibitor differs 
from that observed in the general population, maternal treatment with simvastatin  may reduce 
the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis. 
Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering 
medicinal products during pregnancy should have little impact on the long-term risk 
associated with primary hypercholesterolaemia. For these reasons, simvastatin should not be 
used in women who are pregnant, trying to become pregnant or suspect they are pregnant. 
Treatment with simvastatin should be suspended for the duration of pregnancy or until it has 
been determined that the woman is not pregnant. (See section 4.3). 
 
Lactation 
It is not known whether simvastatin or its metabolites are excreted in human milk. Because 
many medicinal products are excreted in human milk and because of the potential for serious 
adverse reactions, women taking simvastatin should not breast-feed their infants (see section 
4.3). 
 
4.7  Effects on ability to drive and use machines 
Simvastatin has no or negligible influence on the ability to drive and use machines.  
 
However, when driving vehicles or operating machines, it should be taken into account that 
dizziness has been reported rarely in post-marketing experiences. 
 
4.8 Undesirable  effects 
 The frequencies of the following adverse events, which have been reported during clinical 
studies and/or post-marketing use, are categorized based on an assessment of their incidence 
rates in large, long-term, placebo-controlled, clinical trials including HPS and 4S with 20,536 
and 4,444 patients, respectively (see section 5.1). For HPS, only serious adverse events were 
recorded as well as myalgia, increases in serum transaminases and CK. For 4S, all the adverse 
events listed below were recorded. If the incidence rates on simvastatin were less than or 
similar to that of placebo in these trials, and there were similar reasonably causally related 
spontaneous report events, these adverse events are categorized as ‘rare’.  
 
In HPS (see section 5.1) involving 20,536 patients treated with 40mg/day of simvastatin 
(n=10,269) or placebo (n=10,267), the safety profiles were comparable between patients 
treated with simvastatin  40 mg and patients treated with placebo over the mean 5 years of the 
study. Discontinuation rates due to side effects were comparable (4.8 % in patients treated 
with simvastatin 40mg compared with 5.1% in patients treated with placebo). The incidence 
of myopathy was <0.1% in patients treated with simvastatin  40 mg. Elevated transaminases 
(>3 x ULN confirmed by repeat test) occurred in 0.21 % (n=21) of patients treated with 
simvastatin 40mg compared with 0.09% (n = 9) of patients treated with placebo.  
 
The frequencies of adverse events are ranked according to the following: Very common (> 
1/10), Common (≥ 1/100, <1/10), Uncommon (≥ 1/1000, <1/100), Rare (≥ 1/10,000, 
<1/1000), Very Rare (<1/10,000) including isolated reports.  
 
Blood and lymphatic system disorders:  
Rare: anaemia 
 
Nervous system disorders:  
Rare: headache, paresthesia, dizziness, peripheral neuropathy 
 
Gastrointestinal disorders: 
Rare: constipation, abdominal pain, flatulence, dyspepsia, diarrhoea, nausea, vomiting, 
pancreatitis 
 
Hepato-biliary disorders: 
Rare: hepatitis/jaundice 
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Skin and subcutaneous tissue disorders: 
Rare: rash, pruritus, alopecia 
 
Musculoskeletal, connective tissue and bone disorders: 
Rare: myopathy, rhabdomyolysis (see section 4.4), myalgia, muscle cramps 
General disorders and administration site conditions:  
Rare: asthenia  
 
An apparent hypersensitivity syndrome has been reported rarely which has included some of 
the following features: angioedema, lupus-like syndrome, polymyalgia rheumatica, 
dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis and 
arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise. 
 
Investigations: 
Rare: increases in serum transaminases (alanine aminotransferase, aspartate aminotransferase, 
γ-glutamyl transpeptidase) (see section 4.4 Hepatic effects), elevated alkaline phosphatase; 
increase in serum CK levels (see section 4.4). 
 
4.9 Overdose 
To date, a few cases of overdosage have been reported; the maximum dose was 3.6 g. All 
patients recovered without sequelae. There is no specific treatment in the event of overdose. In 
this case, symptomatic and supportive measures should be adopted. 
 
5 PHARMACOLOGICAL  PROPERTIES 
5.1 Pharmacodynamic  properties 
Pharmacotherapeutic group: HMG-CoA reductase inhibitor 
ATC-Code: C10A A01 
 
After oral ingestion, simvastatin, which is an active lactone, is hydrolyzed in the liver to the 
corresponding active beta-hydroxyacid form which has a potent activity in inhibiting HMG-
CoA reductase (3 hydroxy – 3 methylglutaryly CoA reductase). This enzyme catalyses the 
conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthesis of 
cholesterol.  
 
Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations. LDL 
is formed from very-low-density protein (VLDL) and is catabolised predominantly by the 
high affinity LDL receptor. The mechanism of the LDL-lowering effect of ‘Simvastatin 
tablets’ may involve both reduction of VLDL-chlolestrol (VLDL-C) concentration and 
induction of the LDL receptor, leading to reduced production and increased catabolism of 
LDL-C. Apolipoprotein B also falls substantially during treatment with ‘Simvastatin tablets’. 
In addition, ‘Simvastatin tablets’ moderately increases HDL-C and reduces plasma TG. As a 
result of these changes the ratios of total to HDL-C and LDL-to HDL-C are reduced. 
 
High Risk of Coronary Heart Disease (CHD) or Existing Coronary Heart Disease 
In the Heart Protection Study (HPS), the effects of therapy with Simvastatin tablets were 
assessed in 20,536 patients (age 40-48 years), with or without hyperlipidaemia, and with 
coronary heart disease, other occlusive arterial disease or diabetes mellitus. In this study, 
10,269 patients were treated with simvastatin tablets 40mg/day and 10,267 patients were 
treated with placebo for a mean duration of 5 years. At baseline, 6,793 patients (33 %) had 
LDL-C levels below 116 mg/dL; 5,063 patients (25 %) had levels between 116 mg/dL and 
135mg/dL; and 8,680 patients (42 %) had levels greater than 135 mg/dL. 
 
Treatment with Simvastatin tablets 40 mg/day compared with placebo significantly reduced 
the risk of all cause mortality (1328 [12.9%] for simvastatin-treated patients versus 1507 [14.7 
%] for patients given placebo; p=0.0003), due to an 18% reduction in coronary death rate (587 
[5.7 %] versus 707 [6.9 %]; p=0.0005; absolute risk reduction of 1.2 %). The reduction in 
non-vascular deaths did not reach statistical significance. ‘Simvastatin tablets’ also decreased 
the risk of major coronary events (a composite endpoint comprised of non-fatal MI or CHD 
death) by 27 % (p<0.0001). Simvastatin tablets reduced the need for undergoing coronary 
revascularization procedures (including coronary artery bypass grafting or percutaneous 
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transluminal coronary angioplasty) and peripheral and other non-coronary revascularization 
procedures by 30 % (p<0.0001) and 16 % (p = 0.006), respectively. Simvastatin tablets 
reduced the risk of stroke by 25 % (p<0.0001), attributable to a 30 % reduction in ischemic 
stroke (p<0.0001). In addition, within the subgroup of patients with diabetes, simvastatin 
tablets reduced the risk of developing macrovascular complications, including peripheral 
revascularization procedures (surgery or angioplasty), lower limb amputations, or leg ulcers 
by 21 % (p = 0.0293). The proportional reduction in event rate was similar in each subgroup 
of patients studied, including those without coronary disease but who had cerebrovascular or 
peripheral artery disease, men and women, those aged either under or over 70 years at entry 
into study, presence or absence of hypertension, and notably those with LDL cholesterol 
below 3.0 mmol/l at inclusion.  
 
In the Scandinavian Simvastatin Survival Study (4S), the effect of therapy with simvastatin on 
total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 
mg/dL (5.5-8.0 mmol/L). In this multicenter, randomised, double-blind, placebo controlled 
study, patients with angina or a previous myocardial infarction (MI) were treated with diet, 
standard care, and either simvastatin  20-40 mg/day (n = 2,221) or placebo (n=2,223) for a 
median duration of 5.4 years. Simvastatin tablets reduced the risk of death by 30 % (absolute 
risk reduction of 3.3 %). The risk of CHD death was reduced by 42 % (absolute risk reduction 
of 3.5 %). Simvastatin also decreased the risk of having major coronary events (CHD death 
plus hospital-verified and silent nonfatal MI) by 34 %. Furthermore, simvastatin significantly 
reduced the risk of fatal plus nonfatal cerebrovascular events (stroke and transient ischemic 
attacks) by 28 %. There was no statistically significant difference between groups in non-
cardiovascular mortality.  
 
Primary Hypercholesterolaemia and Combined Hyperlipidaemia 
In studies comparing the efficacy and safety of simvastatin 10, 20, 40 and 80 mg daily in 
patients with hypercholesterolaemia, the mean reductions of LDL-C were 30, 38, 41 and 47%, 
respectively. In studies of patients with combined (mixed) hyperlipidaemia on simvastatin 40 
mg and 80 mg, the median reductions in triglycerides were 28 and 33 % (placebo: 2 %), 
respectively, and mean increases in HDL-C were 13 and 16 % (placebo: 3 %), respectively. 
 
5.2 Pharmacokinetic  properties 
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding 
beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Hydrolysis takes place mainly in 
the liver; the rate of hydrolysis in human plasma is very slow. 
 
Absorption 
In man simvastatin is well absorbed and undergoes extensive hepatic first –pass extraction. 
The extraction in the liver is dependant on the hepatic blood flow. The liver is the primary site 
of action of the active form. The availability of the beta-hydroxyacid to the systematic 
circulation following an oral dose of simvastatin was found to be less than 5 % of the dose. 
Maximum plasma concentration of active inhibitors is reached approximately 1-2 hours after 
administration of simvastatin. Concomitant food intake does not affect the absorption. 
 
The pharmacokinetics of single and multiple doses of simvastatin showed that no 
accumulation of medicinal product occurred after multiple dosing.  
 
Distribution 
The protein binding of simvastatin and its active metabolite is >95 %. 
 
Elimination 
Simvastatin is a substrate of CYP3A4 (see sections 4.3 and 4.5). The major metabolites of 
simvastatin present in human plasma are the beta-hydroxyacid and four additional active 
metabolites. Following an oral dose of radioactive simvastatin to man, 13 % of the 
radioactivity was excreted in the urine and 60 % in the faeces within 96 hours. The amount 
recovered in the faeces represents absorbed medicinal product equivalents excreted in bile as 
well as unabsorbed medicinal product. Following an intravenous injection of the beta-
hydroxyacid metabolite, its half-life averaged 1.9 hours. An average of only 0.3 % of the IV 
dose was excreted in urine as inhibitors.  
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5.3  Preclinical safety data 
Based on conventional animal studies regarding pharmacodynamics, repeated dose toxicity, 
genotoxicity and carcinogenicity, there are no other risks for the patient than may be expected 
on account of the pharmacological mechanism. At maximally tolerated doses in both the rat 
and the rabbit, simvastatin produced no foetal malformations, and had no effects on fertility, 
reproductive function or neonatal development.  
 
6 PHARMACEUTICAL  PARTICULARS 
6.1  List of excipients 
Lactose, anhydrous 
Cellulose, microcrystalline 
Maize starch, pregelatinised 
Butyl-hydroxyanisole (E320) 
Magnesium stearate 
Talc 
Hyprolose 
Hypromellose 
Titanium dioxide (E 171) 
 
6.2 Incompatibilities 
None. 
 
6.3 Shelf  life 
3 years 
 
6.4  Special precautions for storage 
Do not store above 25° C. Store in the original package. 
 
6.5  Nature and contents of container 
PVC/PE/PVDC/aluminium blisters- Each blister contains either 10 or 14 tablets to give pack 
sizes of 14, 28, 30, 56, 60 or 100 tablets, 
 
PVC/PE/PVDC/aluminium blisters in polyester/aluminium/PE sachets, - Each blister contains 
either 10 or 14 tablets. The blisters will be enclosed in a sachet to give pack sizes of 14, 28, 
30, 56, 60 or 100 tablets. These sachets will then be placed in an outer carton. 
 
HDPE container with child-proof PP closure and aluminium original seal. . The containers are 
available in pack sizes of 100’s and 500’s.  
 
Not all pack sizes may be marketed. 
 
6.6  Special precautions for disposal 
Not applicable 
 
7 MARKETING  AUTHORISATION HOLDER 
Bristol Laboratories Ltd. 
Unit 3 
Canalside 
Northbridge Road 
Berkhamsted 
Hertfordshire 
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UK 
 
8 MARKETING  AUTHORISATION NUMBER(S) 
PL 17907/0127 
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      13/09/2007 
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